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ABSTRACT 
 
A pressing need exists to develop an improved bone replacement to treat the millions 
of non-union fractures that occur each year as a result of severe trauma, tumor resection, 
spinal fusions, and joint replacements. Current bone grafts are often hindered by a lack of 
biodegradability, porosity or innate ability to promote regeneration. This work employs 
tissue engineering to design a novel bone replacement that combines the regenerative 
potential of autologous tissue with the tunability of synthetic grafts. This is accomplished 
by engineering a biodegradable scaffold with physical and mechanical properties 
emulating those of cancellous bone and combining this scaffold with technologies that 
allow for the controlled delivery of stem cells and osteoinductive factors.  
In this work, polymerized high internal phase emulsions (polyHIPEs) were developed 
as an injectable, high porosity bone graft. Thiol-methacrylate polyHIPEs were 
investigated to increase resistance to oxygen inhibition and improve scaffold function 
under clinically relevant conditions. Methods were established to modulate and 
characterize scaffold porosity, cure rate, compressive properties, and degradation rates. 
Furthermore, cell-laden poly(ethylene glycol)-dithiothreitol hydrogels were developed to 
improve loading and distribution of human mesenchymal stem cells (hMSCs) within 3D 
printed polyHIPEs. This approach allowed for increased cell retention and supported 
critical markers of osteoblastic differentiation. Finally, to confer additional osteoinductive 
character, porous microspheres with tunable release kinetics and requisite compressive 
properties were fabricated using a solvent-free, in-line loading approach. Bioactivity 
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retention of encapsulated bone morphogenetic protein-2, along with its ability to promote 
osteoblastic differentiation of hMSCs, was explored. 
Overall, these studies highlight the strong potential of polyHIPE scaffolds to serve as 
an improved bone replacement with the ability to actively guide bone regeneration. Key 
technologies have been developed that allow for fabrication of a bone graft with improved 
function in a clinically relevant setting, efficient seeding with mesenchymal stem cells, 
and targeted delivery of osteoinductive factors. Fundamentally, this work will be an 
invaluable tool in identifying and evaluating critical design requirements for future bone 
graft design. 
 
 
 
 
 
 
 
 
 iv 
 
DEDICATION 
 
To all who helped me see that where you start doesn’t have to determine where you 
finish. 
 
 
 v 
 
ACKNOWLEDGEMENTS 
 
I can’t adequately express the appreciation I feel for all those who have helped me 
over the past five years. Graduate school has been one of the most transformative periods 
of my life, not just professionally, but personally as well. These experiences have opened 
up opportunities and ways of thinking that I could have never imagined even a few short 
years ago, and helped me prove to myself that our success in life is not determined by our 
beginnings. 
First, thank you to my advisor, Dr. Elizabeth Cosgriff-Hernandez, for taking a chance 
and offering me an opportunity in her lab, even before I truly knew what it meant to be a 
graduate student. You have helped me see and appreciate my strengths and challenged me 
to grow and overcome my weaknesses. I will always be grateful for your patience and 
guidance in helping me achieve something that I had never imagined possible. 
Thank you to my committee, Dr. Akhilesh Gaharwar, Dr. Roland Kaunas, and Dr. 
Brian Saunders, for your wonderful insight and guidance through this process. I have 
greatly enjoyed learning from and working alongside you. Thank you to the LSAMP 
community for your support, encouragement, and constant reminder of what is possible. 
As challenging and rewarding as this adventure has been, it has been made so much 
more enjoyable being surrounded and supported by great lab mates. I’m forever indebted 
to Bobby Moglia and Jenny Robinson for your patience and generosity in teaching me all 
the basics of research. To the original IBT crew, Alysha Kishan and Allison Post, for the 
laughs, encouragement and research support during a time when we were all trying to 
 vi 
 
figure out how to survive in graduate school. To Nick Sears, for being a great source of 
knowledge and inspiring me to not just think outside the box, but to build a new box. To 
Thomas Wilems, for your insightful advice and mentoring as I finished up my studies. To 
Prachi Dhavalikar, for your tremendous help with the encapsulation work and always 
making me feel far more confident than I actually was. To Sahar Mohiuddin, for your 
steadfast reliability and patience with my inability to multitask. To Gabriel Rodriguez-
Rivera for your innovative ideas and willingness to explore new directions. To all the 
members of the UT team, Taneidra Buie, Ziyang Lan, Siliang Wu and Megan Wancura 
for your willingness to always help, give new ideas and share a kind word. And to Stacy 
Cereceres, for leading Team College Station to the finish line with a joyous outlook, 
unquestionable selflessness, and most importantly, lasting friendship. 
Finally, to my wife, the constant that holds my life together and the person I strive to 
be. I can never thank you enough for the support, sacrifice and love you have given during 
this process. Anything I am able to do is only because I know that I have you beside me. 
  
 vii 
 
CONTRIBUTORS AND FUNDING SOURCES 
 
This work was supported by a dissertation committee consisting of Dr. Elizabeth 
Cosgriff-Hernandez (chair), Dr. Akhilesh Gaharwar (co-chair) and Dr. Roland Kaunas 
(member) of the Department of Biomedical Engineering, and Dr. William B. Saunders 
(member) of the Department of Veterinary Small Animal Clinical Sciences.  
Animal studies and histological analysis for Chapter II was performed by Dr. William 
B. Saunders. Reporter cells utilized in Chapter IV were generously provided by the lab of 
Dr. Daniel Alge. All other work conducted for the dissertation was completed 
independently.  
Graduate study was supported by The Texas A&M LSAMP NSF Bridge to the 
Doctorate Fellowship and the Texas A&M Dissertation Fellowship. 
 
 viii 
 
NOMENCLATURE 
 
APS Ammonium Persulfate 
BDMA 1,4 Butane Diol Dimethacrylate 
BMP Bone Morphogenetic Protein 
BPO Benzoyl Peroxide 
BRITIER BMP Responsive Reporter Cell Line 
DTT Dithiothreitol 
ECM Extracellular Matrix 
EGDMA Ethylene Glycol Dimethacrylate 
FBS Fetal Bovine Serum 
FGF Fibroblast Growth Factor 
GM Growth Media 
hMSC Human Mesenchymal Stem Cell 
HQ Hydroquinone 
IG Iron Gluconate Dihydrate 
IGF Insulin-like Growth Factor 
OM Osteogenic Media 
PBS Phosphate Buffered Saline 
PDGF Platelet Derived Growth Factor 
PEG Poly(ethylene glycol) 
PFDMA Propylene Fumarate Dimethacrylate 
 ix 
 
PGPR Polyglycerol polyricinoleate 
PLA Poly(lactic acid) 
PLGA Poly(lactide-co-glycolide) 
PMMA Poly(methyl methacrylate) 
PolyHIPE Polymerized High Internal Phase Emulsion 
RGD Arginine-Glycine-Aspartic Acid 
TGF Transforming Growth Factor 
TMA 4, N,N - Trimethylaniline 
VEGF Vascular Endothelial Growth Factor 
 x 
 
TABLE OF CONTENTS 
 
Page 
ABSTRACT .......................................................................................................................ii 
DEDICATION .................................................................................................................. iv 
ACKNOWLEDGEMENTS ............................................................................................... v 
CONTRIBUTORS AND FUNDING SOURCES ............................................................vii 
NOMENCLATURE ....................................................................................................... viii 
TABLE OF CONTENTS ................................................................................................... x 
LIST OF FIGURES ..........................................................................................................xii 
LIST OF TABLES .......................................................................................................... xvi 
CHAPTER I  INTRODUCTION AND LITERATURE REVIEW ................................... 1 
1.1. Clinical Overview ........................................................................................... 1 
1.2. Current Treatment Options ............................................................................. 4 
1.3. Tissue Engineered Scaffolds .......................................................................... 5 
1.4. Mesenchymal Stem Cells in Bone Tissue Engineering .................................. 9 
1.5. Growth Factor Delivery in Bone Tissue Engineering .................................. 17 
1.6. Summary and Approach ............................................................................... 23 
CHAPTER II  THIOL-METHACRYLATE POLYHIPES WITH IMPROVED 
RESISTANCE TO OXYGEN INHIBITION .................................................................. 25 
2.1. Introduction .................................................................................................. 25 
2.2. Materials and Methods ................................................................................. 29 
2.3. Results and Discussion ................................................................................. 40 
2.4. Conclusions .................................................................................................. 64 
CHAPTER III  IMPROVED IN SITU SEEDING OF 3D PRINTED BONE GRAFTS 
USING CELL-RELEASING HYDROGELS .................................................................. 65 
3.1. Introduction .................................................................................................. 65 
3.2. Materials and Methods ................................................................................. 69 
3.3. Results and Discussion ................................................................................. 75 
 xi 
 
3.4. Conclusions .................................................................................................. 92 
CHAPTER IV  TUNABLE RELEASE OF BMP-2 FROM POROUS POLYHIPE 
MICROSPHERES ............................................................................................................ 93 
4.1. Introduction .................................................................................................. 93 
4.2. Materials and Methods ................................................................................. 96 
4.3. Results and Discussion ............................................................................... 103 
4.4. Conclusions ................................................................................................ 117 
CHAPTER V  CONCLUSIONS .................................................................................... 118 
5.1. Summary .................................................................................................... 118 
5.2. Significance of Work .................................................................................. 120 
5.3. Challenges and Future Directions .............................................................. 123 
REFERENCES ............................................................................................................... 128 
 
 xii 
 
LIST OF FIGURES 
 
Page 
Figure 2.1. Molecular structure of propylene fumarate dimethacrylate (PFDMA) (A) 
and pentaerythritol tetrakis(3-mercaptoproprionate) (tetrathiol)  (B). 
Reprinted from Whitely et al.146 ....................................................................... 32 
Figure 2.2. Representative scanning electron microscopy (SEM) micrographs of 
PFDMA (A), PFDMA-5T (B), and PFDMA-10T (C) polyHIPE pore 
architecture. Reprinted from Whitely et al.146 .................................................. 41 
Figure 2.3. Storage modulus during polymerization of polyHIPE (A) and work and set 
times (B) of polyHIPEs cured at 37 °C with 1.0 wt% initiator and reducing 
agent. Reprinted from Whitely et al.146 ............................................................ 43 
Figure 2.4. The effect of increasing tetrathiol concentration on average gel fraction for 
high surface-area-to-volume ratio polyHIPEs cured under ambient and low 
oxygen conditions (A) and bulk cured polyHIPEs cured under ambient 
conditions (B). Reprinted from Whitely et al.146 .............................................. 46 
Figure 2.5. The effect of hydroquinone inhibitor (A) on average storage time (B), work 
and set time (C), and gel fraction (D) of thiol-methacrylate polyHIPEs. 
Reprinted from Whitely et al.146 ....................................................................... 49 
Figure 2.6. The effect of increasing tetrathiol concentration on polyHIPE compressive 
modulus (A) and yield strength (B). Reprinted from Whitely et al.146 ............. 50 
Figure 2.7. The effect of increasing tetrathiol concentration on polyHIPE degradation 
up to 4 weeks in 0.25 M NaOH (A) and 0.5 M NaOH (B). Reprinted from 
Whitely et al.146 ................................................................................................ 53 
Figure 2.8. hMSC viability after 24 h incubation with two concentrations of PFDMA 
and PFDMA-10T extracts (1.0 and 0.5 vol%) (A). Micrographs illustrating 
live (green) and dead (red) cells cultured with respective polyHIPE extracts 
at 0.5 vol% (B). Reprinted from Whitely et al.146 ............................................ 55 
Figure 2.9. NMR spectrum of PFDMA and PFDMA-10T polyHIPE extracts. Reprinted 
from Whitely et al.146 ........................................................................................ 55 
Figure 2.10. hMSC viability on PFDMA and PFDMA-10T polyHIPEs at 1, 3, and 7 
days (A). Micrographs illustrating live (green) and dead (red) cells on the 
respective polyHIPE sections at 7 days (B). Reprinted from Whitely et al.146 57 
 xiii 
 
Figure 2.11. Proliferation of hMSCs seeded on PFDMA and PFDMA-10T polyHIPEs 
at 1, 6, and 11 days as determined by DNA quantification. hMSCs were 
cultured in growth media (GM) and osteogenic media (OM) with an initial 
cell seeding density was 50,000 cells/cm2. Reprinted from Whitely et al.146 .. 57 
Figure 2.12. Alkaline phosphatase activity of hMSCs seeded on PFDMA and PFDMA-
10T polyHIPEs at 1, 6, and 11 days. PolyHIPEs were cultured in growth 
media (GM) (A) and osteogenic media (OM) (B). Reprinted from Whitely et 
al.146 .................................................................................................................. 59 
Figure 2.13. The effect of gelatin surface modification on collagen staining (A), 
attached hMSC viability (B), hMSC adhesion (C), and hMSC morphology 
and spreading (D) of polyHIPE scaffolds. ........................................................ 61 
Figure 2.14. Biocompatibility of polyHIPE in rat calvarial defect model. A: Negative 
control defects contain neovascularization (arrowheads), spindle shaped 
fibroblasts, and collagenous matrix. B: The polyHIPE treated defect contains 
similar fibrous tissue (arrowheads). C: Ordinal scoring of negative control 
and polyHIPE (n = 6 tissue sections) indicated no significant differences in 
the biologic response, except for lymphocyte infiltrate, which was increased 
in polyHIPEs. .................................................................................................... 63 
Figure 2.15. Rabbit medial femoral condyle defect with diameter 3.5 mm and depth of 
5 mm (white arrow) (A). PolyHIPE injected into the defect (B). PolyHIPE 
interdigitates with the bone, and solidifies (black arrow) (C). Harvested and 
sectioned image of the filled defect (D), and representative SEM images of 
the injected polyHIPE (E) and bone/graft interface (F). ................................... 63 
Figure 3.1 Schematic illustrating hMSCs loading in hydrogel precursor solutions (A), 
injection and encapsulation in 3D printed polyHIPE scaffold (B), and 
protection during early stages of implantation (C). .......................................... 67 
Figure 3.2. Effect of initiator concentration and reducing agent ratio on gelation onset 
(A) and complete network formation (B) of hydrogel carrier. The + represents 
a gelation and network formation time of greater than 30 minutes. The * 
represents a gelation onset time of less than 10 seconds. All data represents 
average ± standard deviation for n = 3. ............................................................ 77 
Figure 3.3. Percent hMSC viability following 10 min exposure to redox agents, 
ammonium persulfate and iron gluconate (A); 24h additional culture (B). 
Percent hMSC viability and cell density following carrier encapsulation with 
micrographs illustrating live (green) and dead (red) cells in respective 
hydrogel formulations (C). All data represents average ± standard deviation 
for n = 12. The * and ° represent significant difference (p<0.05) for 25 mM 
concentration compared to other concentrations. ............................................. 82 
 xiv 
 
Figure 3.4. Micrographs illustrating live (green) and dead (red) cells 1 day post 
encapsulation and 7 days post release onto TCPS and polyHIPE substrates 
(A). Percent hMSC viability 1 day and 7 days following release and 
attachment onto TCPS and polyHIPE substrates (B). All data represents 
average ± standard deviation for n = 12. .......................................................... 84 
Figure 3.5. Distribution of hMSCs using carrier seeding onto multilayer polyHIPE 
scaffolds determined by dsDNA quantification and compared to suspension 
seeding control (A). Representative micrographs of top, middle and bottom 
layers of scaffold (B). All data represents average ± standard deviation for n 
= 3. The * represents significant difference (p<0.05) between suspension and 
carrier seeding at specified layer. ..................................................................... 86 
Figure 3.6. Adhesion of hMSCs released onto TCPS and polyHIPE substrates 
determined by dsDNA quantification (A). Alkaline phosphatase activity of 
hMSCs 7D and 14D post carrier release. Cells were cultured in growth media 
(GM) and osteogenic media (OM) as positive control. All data represents 
average ± standard deviation for n = 3. The * and ° represent significant 
difference (p<0.05) for TCPS substrates compared to polyHIPEs at indicated 
time points. The + represents significant difference (p<0.05) for ALP activity 
on polyHIPE substrates at 14D. ........................................................................ 88 
Figure 3.7. Alizarin red staining of hMSC cultures 4 weeks following carrier release. 
hMSC mineralization post release onto TCPS substrates in growth vs 
osteogenic media (A). Effect of release substrate (TCPS vs polyHIPE) and 
media conditions (growth vs osteogenic) on hMSC mineralization (B). Semi-
quantitative analysis of mineralization determined by alizarin red stain 
recovery (C). All data represents average ± standard deviation for n = 4. The 
* represents significant difference (p<0.05) between all compositions. .......... 89 
Figure 3.8. Effect of scaffold chemistry (PFDMA vs PLA films) and scaffold porosity 
(PFDMA polyHIPE vs PFDMA film) on calcium deposition in cell free 
conditions (A). Quantification of hMSC adhesion on varied substrate 
determined by dsDNA quantification (B). Effect of substrate on hMSC 
alkaline phosphatase activity after 14 days (C). Cells were cultured in growth 
media (GM) and osteogenic media (OM) as positive control. All data 
represents average ± standard deviation for n = 4. The * represents significant 
difference (p<0.05) for indicated composition compared to all others in 
respective media. .............................................................................................. 91 
Figure 4.1. Schematic of microsphere fabrication. HIPE is injected through a needle 
parallel to the flow of 3 wt% PVA solution and polymerized via UV 
irradiation. Polymerized particles are collected and filtered prior to use. ........ 98 
 xv 
 
Figure 4.2. Modulated particle diameter of model compositions with representative 
SEM micrographs (A-D). Modulated pore diameter of model compositions 
with representative SEM micrographs (E-H). From left to right: large 
particle-small pore, large particle-large pore, small particle-small pore, small 
particle-large pore. .......................................................................................... 104 
Figure 4.3. Tuning release profiles of BSA-FITC from polyHIPE microspheres. Daily 
and cumulative release profiles for all model compositions (A). Effect of 
particle size on release kinetics for large (45um) and small (15um) pore size 
(B). Effect of pore diameter on release kinetics for large (900um) and small 
(300um) particle size (C). All data represents average ± standard deviation 
for n = 3. ......................................................................................................... 109 
Figure 4.4. Normalized FFLuc activity of BRITER cell line treated with releasates 
taken from rhBMP-2 loaded microspheres. Percent bioactivity retention 
determined by comparison to FFLuc of known rhBMP-2 stocks. .................. 111 
Figure 4.5. Effect of rhBMP-2 loaded polyHIPE releasate on cell density (A) and 
alkaline phosphatase activity (B) of hMSCs cultured with releasate for 14 
days. Cells were cultured in fresh solution of stock rhBMP-2 (BMP-2) and 
osteogenic media (OM) as positive control, and growth media (GM) as 
negative control. All data represents average ± standard deviation for n = 4. 
The * and ° represent significant difference (p<0.05) between BMP-2 or GM 
and indicated compositions for density or ALP activity. ............................... 113 
Figure 4.6. Effect of microsphere particle size and pore size on composite scaffold 
compressive modulus and strength for 5 wt% incorporation using four model 
compositions (A). Effect of increasing microsphere incorporation (5, 10 and 
20 wt%) on composite scaffold compressive modulus and strength (B). All 
data represents average ± standard deviation for n = 3. The * and ° represent 
significant difference (p<0.05) for 20 wt% compressive modulus or strength 
and other indicated compositions. .................................................................. 116 
 
 xvi 
 
LIST OF TABLES 
 
Page 
Table 1.1. Trophic activity and therapeutic effects of mesenchymal stem cells. ............. 13 
Table 1.2. Role of growth factors in bone repair.............................................................. 18 
Table 3.1. Effect of initiator and reducing agent concentration on hydrogel compressive 
modulus, swelling rato, and gel fraction. .......................................................... 79 
Table 4.1. Summary table of fabrication parameters including tubing diameter, needle 
size, flow rate, and surfactant compositions for model compositions. ............. 98 
Table 4.2. Summary table of properties for model compositions including particle 
diameter (n=25), pore size (n=100), and loading efficiency (n=12). All data 
represents average ± standard deviation. ........................................................ 104 
 
 
 
 
 
 1 
 
CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
1.1.  Clinical Overview 
1.1.1.  Prevalence of Nonunion Bone Defects 
Treatment of musculoskeletal injury and disease are among the most common 
procedures performed annually in the United States, with an estimated financial burden of 
greater than $200 billion.1 Specifically, bone fractures comprise a majority of these 
disorders with over seven million reported cases in the United States. These defects arise 
from treatment of traumatic injury, congenital defect, tumor resection, and joint 
replacements. Unfortunately, it is estimated that up to 10 percent of these fractures will be 
associated with delayed or total absence of bone union during healing.2 Several factors 
influence nonunion development including patient age and health, location of the injury 
site, damage to surrounding tissue and vasculature, and mechanical instability.3 In cases 
with significantly high loss of bone tissue, proper stabilization and control of the injury 
site alone is not sufficient to promote healing. These defects, termed critical size, are 
defined as osseous defects that fail to heal spontaneously with bone during the lifetime of 
the patient, unless a suitable bone replacement material is placed in or onto the defect.4 
Without intervention, these defects fill primarily with fibrous connective tissue and fail to 
recapitulate the structure of native bone. As a result of this dependence on a secondary 
substrate to facilitate bone healing, critical size defects are an ideal platform to investigate 
novel bone replacement materials. Clinically, critical size may be determined through 
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radiological analysis of defect geometry. Key’s hypothesis states that a segmental long 
bone defect greater than 1.5X the diaphyseal diameter will fail to undergo complete 
healing in canine models.5 Furthermore, researchers have explored and identified similar 
effects of segmental defect length and diaphyseal diameter on healing in other animal 
models including sheep, cat and rabbit.6 
1.1.2.  Bone Biology and Structure 
Bone is a nanocomposite of a stiff mineralized hydroxyapatite matrix and elastic 
collagen fibrils. Inorganic hydroxyapatite mineral comprises approximately 70% of 
calcified bone with 25% consisting of organic material (including cells), and 5% water.7 
Newly synthesized osteoids that have yet to be mineralized consist primarily of collagen 
(greater than 90%) with the remainder consisting of bone specific growth factors and 
proteoglycans. Cortical and cancellous bone make up the two distinct tissue architectures 
present in bone. The robust mechanical properties and load bearing potential is provided 
by the cortical layer, a primarily non-porous architecture making up 80% of skeletal tissue. 
Compressive modulus of cortical bone has been estimated at an impressive 17 GPa with 
tensile properties about 20% weaker. The inner architecture of bone consists of a spongey, 
honeycomb-like structure known as cancellous bone. As a result of this improved porosity 
(estimated up to 90%), compressive modulus values are reduced, with an estimated 
modulus of 20-500 MPa.8. Cancellous bone is typically found in the metaphysis of long 
bones while cortical bone makes up the diaphysis. The cortical layer of bone is surrounded 
by a thin membrane known as the periosteum, which contains many progenitor cells 
responsible for bone maintenance. Bone maintenance is governed by complex interactions 
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and feedback mechanisms between matrix producing osteoblasts and tissue-resorbing 
osteoclasts. The majority of cells in adult skeleton consist of osteocytes, fully specialized 
osteoblasts which facilitate extracellular calcium and phosphorus concentrations and 
direct osteogenesis.9 Improved understanding of the complex processes and regulators in 
bone remodeling is critical to developing an optimal treatment for critical sized defects.  
1.1.3.  Natural Bone Healing  
Bone is unique among tissues as it has the ability to heal new, healthy tissue with the 
absence of scar tissue formation.10 Fracture healing occurs in multiple phases, often 
occurring simultaneously. During the early stages of repair, disruption of the native 
vasculature results in formation of a hematoma, providing a matrix that encloses the 
wound, allows migration of inflammatory cells, fibroblasts, and progenitor cells into the 
wound site, and promotes granular tissue formation.9, 11 This initial response is followed 
by a rapid release of angiogenic factors and cytokines to direct new blood vessel 
formation, as well as the release of osteoindutive factors from infiltrating stem cells and 
extracellular matrix.12 The next stage is defined by the formation of a soft callus that 
begins to stabilize the defect. Matrix composed of Type 1 collagen and proteoglycans is 
produced by osteoblasts which forms the soft, internal callus, eventually undergoing 
mineralization and forming the bony callus. Simultaneously, intramembranous 
ossification occurs in the periosteum, creating an external callus. The ossification of the 
soft callus to bridge the broken can occur in as little as 4 weeks if properly immobilized. 
Finally, the hard callus is replaced with native bone, with size and vascular structure fully 
returning to normal over a period of several months.13 Similar to healing in non-critical 
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defects, critical defect healing processes include formation of poorly organized endosteal 
and periosteal callus formation that proceed toward bony bridging of the gap. However, 
unlike non-critical healing, full bridging does not occur of the opposing callus parts, 
resulting instead in formation of rounded corticies.14 This nonunion results in the loss of 
load transfer and mechanical stimuli that are needed to fully initiate tissue organization.14, 
15 
1.2.  Current Treatment Options 
1.2.1.  Autografts  
Autologous grafts are currently the gold standard for bone grafting procedures due to 
their high healing capacities. In these procedures, tissue is harvested from a secondary 
location on the patient, most commonly the iliac crest of the hip or tibia, and transplanted 
to the injury site.16 Advantages of autografts include high integration with surround tissue, 
strong osteoinductive character, and no risk of immune rejection. Multiple trials including 
vertebral fusions and treatment of tibial nonunion have demonstrated extremely high 
success rates.17 Unfortunately, this procedure is not an option for many patients due to a 
lack of graft availability and complications arising from a second surgical site.17-19  
1.2.2.  Allografts  
Allograft bone provides a more readily available treatment option as it can be 
harvested from cadaveric tissue donors and easily stored.20 As immune rejection and 
disease transmission can be areas of concern for allogenic transplants, decellularization 
processes are often introduced to reduce potential risks. Similarly to grafting with 
autologous tissue, the complex geometry of bone defects often makes fitting a replacement 
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allograft extremely difficult. As a result, donor tissue can be demineralized to form a 
powder or paste that allows easier implementation and is better able to match defect 
geometry. This processing however, severely compromises load bearing potential, further 
driving the need or a more viable bone replacement.21 
1.2.3.  Alloplastic Grafts 
Poly(methyl methacrylate) (PMMA) bone cement is the most widely utilized synthetic 
material in bone grafting procedures, commonly selected to stabilize implants, fill defects 
in tumor resection, and provide minor load bearing in spinal procedures.22, 23 Despite 
widespread use, PMMA cements are not an ideal treatment option as they are nonporous, 
do not undergo necessary biodegradation, and often reach temperatures in excess of 100ºC 
during polymerization, which can lead to necrosis of the surrounding tissue. In contrast, 
calcium phosphate cements have been readily explored as a more cytocompatible and 
osteoinductive bone replacement.1 Despite success, these grafts often exhibit low fracture 
toughness and fail due to fracture.24 Combined, these limitations suggest that physicians 
and patients would greatly benefit from an improved bone grafting option. 
1.3.  Tissue Engineered Scaffolds 
Tissue engineering aims to provide an improved tissue replacement option by 
combining the regenerative capacity of autologous grafts with the tunability and 
availability of synthetic materials.25 The tissue engineering paradigm consists of a 
biomaterial scaffold that temporarily replaces tissue structure, and combining this scaffold 
with appropriate biochemical cues and progenitor cells to facilitate tissue regeneration.26 
As a result, this strategy has numerous advantageous over standard grafting materials.  
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1.3.1.  Scaffold Requirements 
Success as a tissue engineered scaffold is dictated by the ability to support critical cell 
and tissue functions. To achieve this, it is necessary to have sufficiently interconnected 
and porous architecture to allow cellular infiltration, vascularization, and nutrient and 
waste transport. Multiple groups have explored optimal pore sizes needed to encourage 
ingrowth and osteogenesis. Broadly, a minimum pore size of 100 microns is desired, with 
larger pores demonstrating increased osteoblastic activity.27-29 Native bone is unique in its 
ability to achieve a porous architecture while maintaining the ability to withstand high 
physiological loads. Typical physiological stresses have been estimated up to 50 MPa with 
highest stresses occurring in the femur during strenuous activities such as running.30 
Achieving this combination of porosity and strength in a synthetic material, without 
introducing negative stress-shielding effects, has been a major hurdle in bone grafting.31 
It is generally accepted that scaffolds with compressive properties approaching those of 
cancellous bone (100 MPa modulus; 10 MPa strength) are capable of supporting bone 
regeneration.32 Finally, an ideal tissue engineered scaffold should degrade at a rate similar 
to de novo tissue formation, and appropriately transfer responsibility back to the healing 
tissue.26 Femoral defect models in rabbits have illustrated improved healing when tissue 
engineered scaffolds are tuned to degrade at a rate that better matches healing.33 Matching 
regeneration rates can be particular challenging however, as patient age, health, and 
severity of injury effect healing rates. 
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1.3.2.  Scaffold Fabrication Techniques 
A multitude of fabrication techniques have been developed by tissue engineers to 
generate highly porous scaffolds for repair of musculoskeletal injuries. The most 
prominent of these include electrospinning, gas foaming, porogen leaching, and thermally 
induced phase separations. Electrospinning is a method utilized to generate 2-dimensional 
sheets of fibrous meshes that contain high SA/V ratios.34 Tunable porosities, diameters, 
and alignment patterns are achieved through modulation of polymer solution and system 
parameters.35 Lack of suitable compressive properties and inability to generate large 
constructs limit its potential in orthopedic applications. Gas foaming, or blowing, 
techniques are utilized to produce highly porous scaffolds with a range of pore sizes.36 
Pores are generated through gas production, typically CO2, in a polymer melt, utilizing 
chemical or physical processes. Elevated temperatures and post fabrication processes 
needed to remove a non-porous skin relegates this method to solely prefabrication 
applications.37  
Dispersion, and subsequent leaching, of porogens (often salts) from a polymer solution 
after network formation have also yielded porous, interconnected scaffolds.38 A common 
drawback to salt leached scaffolds is the presence of stress concentrations resulting from 
the uncontrolled shape of porogens, which can result in decreased mechanical 
properties.39, 40 Inducing a change in solubility of a polymer solution can be used create 
polymer-rich and polymer-poor regions, that upon subsequent sublimation, yields a 
porous polymer scaffold. Modulating parameters in this phase separation method, 
including polymer type and temperature, can be used to obtain a variety of pore 
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geometries.41, 42 Despite the ability of these techniques to yield porous scaffolds, 
fabrication parameters often introduce concerns or preclude use for in situ delivery, 
incorporation of cells, or use in growth factor delivery.  
1.3.3.  Polymerized High Internal Phase Emulsions (PolyHIPEs) 
 Emulsion templating is a unique fabrication technique that is currently being 
studied for use in tissue engineering.43, 44 High internal phase emulsions are defined by an 
internal droplet phase (greater than 74%), and an organically soluble prepolymer outer 
phase. Polymerization of the continuous phase locks in the internal architecture dictated 
by the droplet phase resulting in highly porous foams. Historically, numerous groups have 
reported on processing variables than can be tuned to achieve a diverse range of properties, 
(75-99% porosity; 1-100 µm pore size; 2 kPa- 60 MPa compressive moduli).43, 45-49 
Recently we developed a polyHIPE scaffold suitable for bone regeneration based on the 
biodegradable macromer, propylene fumarate dimethacrylate (PFDMA). This 
hydrophobic, low viscosity macromer contains ester linkages that allow for hydrolytic 
degradation, and reactive methacrylate end groups that undergo rapid polymerization in 
physiological conditions. Uniquely, we have demonstrated these injectable materials are 
suitable for in situ injection, facilitate osteogenic activity, and adaptable as 3D printable 
emulsion inks. 
1.3.4.  Thiol-Methacrylate Polymerization for Improved Resistance to Oxygen Inhibition 
Although traditional free radical polymerization is a robust mechanism for scaffold 
fabrication, use of only methacrylated macromers in our system renders it susceptible to 
oxygen inhibition. When polymerized under oxygen rich conditions, initiating radicals are 
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scavenged by molecular oxygen and converted to peroxy radicals.50, 51 These radicals are 
no longer able to reinitiate polymerization of methacrylate functional groups, essentially 
terminating cure. This often results in reduced cure rates, poor monomer conversion, and 
reduced mechanical properties. Although many researchers have developed techniques to 
prevent oxygen inhibition in commercial settings (e.g. purging with inert gases), limited 
progress has been made in addressing this problem in an injectable system. Researchers 
have probed Michael addition-type reactions to create ideal, step-growth crosslinked 
networks that provide resistance to oxygen inhibition. Specifically, thiol-acrylate and 
thiol-methacrylate systems have been reported to have improved resistance to oxygen 
inhibition. O’Brient et al. illustrated that increasing thiol concentration in diacrylate 
systems resulted in reduced levels of oxygen inhibition.52 In contrast to the traditional free-
radical polymerization of unsaturated vinyls, thiol-methacrylate polymerization can be 
initiated by both cleave-type initiators and hydrogen abstraction of the thiol monomer, 
rendering it less susceptible to oxygen inhibition. Propagation then proceeds via thiol or 
methacrylic/acrylic radical addition to methacrylate/acrylate functional groups. This 
reduction in oxygen inhibition provided by a mixed mode polymerization mechanism 
could prove a major benefit in an injectable polyHIPE system.  
1.4.  Mesenchymal Stem Cells in Bone Tissue Engineering 
1.4.1.  MSC Discovery and Isolation 
One of the most exciting developments over the past 60 years in regenerative medicine 
is the growth of mesenchymal stem cell therapies.53 Discovered in the 1960’s through the 
ground breaking work of Friedenstein and colleagues, a population of stromal cells that 
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could be isolated from bone marrow, were plastic adherent, and could promote formation 
of de novo bone tissue were discovered.54 Over the next two decades, significant emphasis 
was placed on better understanding these potent sources of healing, termed mesenchymal 
stem cells, and developing markers for their identification.55, 56 Although mesenchymal 
stem cells represent a small portion (less than 0.01%) of total cells present in bone marrow, 
Pittenger et al. demonstrated that these cells could be expanded with high efficiency in 
vitro while retaining their multipotency.57 These studies demonstrated that mesenchymal 
stem cells were capable of differentiating into adipcytic, chondrocytic, and osteocytic 
lineages. Exponential increase in interest led to the release of a position statement by The 
International Society for Cellular Therapy defining minimal criteria for classification of 
multipotent mesenchymal stromal cells as plastic-adherent, positive for expression of 
CD105, CD73, and CD90, ability to differentiate into osteoblasts, adipocytes, and 
chondrocytes.58 
Harvesting of MSCs from bone marrow remains the most widely studied isolation 
method. In humans, the superior iliac crest of the pelvis is commonly selected, with 
additional isolation compartments being those of the femur, tibia, and thoracic and lumbar 
spine.59-61 Large animal models typically utilize similar methods with small animal models 
focusing on harvest from the mid-diaphysis of the tibia or femur. Primary harvests are 
typically kept in culture for two weeks to allow for adherence and removal of non-adherent 
hematopoetic cells.61 More recently, additional stem cell niches have been discovered, 
providing additional sources for tissue-specific stem cells including the periosteum, 
adipose tissue, and umbilical cord blood.62-64 Yoshimura et al. demonstrated that solid 
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tissues could provide higher concentrations of mesenchymal stem cells than marrow 
harvests. 
1.4.2.  Trophic Activity 
The ability of mesenchymal stem cells to differentiate into specialized cell types has 
prompted many researchers to employ these cells in their grafts in the hopes of directly 
replacing the cells lost to injury and responsible for tissue remodeling. Although 
significant improvements in regeneration have been observed as a result of mesenchymal 
stem cell presence, a new school of thought has emerged suggesting an alternative 
therapeutic mechanism.53, 65 It has been evidenced that in many cases, rather than 
specialized differentiation, MSCs were in fact creating a ‘trophic effect’, or that is to say, 
creating a regenerative microenvironment through the secretion of growth factors and 
bioactive molecules that promotes infiltration of native cells, angiogenesis, and tissue 
healing. Common trophic mechanisms are summarized in Table 1.1.53 This trophic 
activity is achieved through the secretion of numerous growth factors to recruit and 
promote proliferation of native cells including transforming growth factors, insulin-like 
growth factor-1, basic fibroblast growth factor and epithelial growth factor.66, 67 
Furthermore, MSCs have been shown to facilitate angiogenesis through secretion of 
vascular endothelial growth factor and stabilizing newly formed vessels.68, 69 Tateishi-
Yuyama et al. demonstrated that autologous implantation of bone marrow derived cells 
could improve angiogenesis in patients suffering from unilateral ischemia of the leg.70 
Another unforeseen benefit of MSC therapy is anti-inflammatory and 
immunomodulatory effects. Inflammation at the site of musculoskeletal injury can result 
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in impediment of healing processes of native progenitor cells. MSCs have been shown to 
secret a multitude of anti-inflammatory factors in response to injury.71 As a result, MSCs 
are able to modulate function of surveilling inflammatory immune cells, including T cells, 
B cells, and macrophages.72, 73 MSC delivery has also demonstrated anti-apoptotic and 
antimicrobial properties. Cselenyak et al. explored the mechanism behind bone marrow 
derived MSCs improving viability of ischemic cariomyoblast populations and identified 
the recovery to be dependent on cell-to-cell interactions.74, 75 hCAP-18/LL-37, a peptide 
commonly expressed by epithelial cells and macrophages to combat bacterial infections, 
is secreted by MSCs in response to e coli and other infections. In an experimental colitis 
and sepsis model, systemic infusion of adipose derived MSCs protected from severe sepsis 
by reducing infiltration of inflammatory cells and by down regulation of inflammatory 
mediators.76 
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Table 1.1. Trophic activity and therapeutic effects of mesenchymal stem cells. 
Properties Mechanism Effect 
Trophic 
Release of TGF-α, TGF-β, 
HGF, EGF, FDF-2, IGF-1 
 
 
Release of VEGF, IGF-1, EGF, 
angiopoietin-1 
 
 
Release of keratinocyte growth 
factor, SDF-1, macrophage 
inflammatory protein-1 α and β 
Direct fibroblasts, 
epithelial, and endothelial 
cells 
 
Recruit endothelial cells 
and facilitate 
vascularization 
 
Reduce scar tissue 
formation 
Immunomodulatory 
Release of prostaglandin 2, 
TGF-β1, HGF, SDF-1, nitrous 
oxide, indoleamine 2,3-
dioxygenase, IL-4, IL-6, IL-10, 
IL-11 receptor antagonist, 
soluble tumor necrosis factor-α 
receptor 
 
Express HLA Class I and HLA 
Class II 
Inhibit function of T  cells, 
killer cells, B cells, 
monocytes, macrophages 
and dendritic cells 
 
 
 
 
Avoid immune system 
recognition 
Apoptotic Rescue 
Secretion of IGF-1, IL-6, 
VEGF, HGF, TGF-β1 
Increase protein kinase B 
production to facilitate anti-
apoptotic pathways 
Antimicrobial 
Express hCAP-18/LL-37 
 
 
Upregulate indoleamine 2,3-
dioxygenase 
Combat Gram-positive and 
negative bacterial 
infections 
 
Regulate T-cell activity 
 
 
 
1.4.3.  Clinical Efficacy of Stem Cell Therapy 
The clinical benefits of marrow derived stem cell delivery have been widely 
established. Early studies focused on the percutaneous grafting of autologous bone 
marrow in nonunion fractures, including those of the tibia. Connolly et al. observed 
improved callus formation and defect union in eighty percent of patients stabilized with 
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an external cast, and one hundred percent of patients stabilized with intramedullary nails. 
Observed results were comparable to standard autologous grafting procedures.77 It was 
later established by Hernigou and colleagues that efficacy of autologous bone marrow 
therapies in the treatment of nonunions was related to the number of progenitors present 
in the graft.78 This work articulated that bone marrow harvesting from the iliac crest may 
be patient variable and not suitable for promotion of healing in the absence of 
concentration, emphasizing the importance of normalizing progenitor amount to reach 
efficacy. Finally, Bruder et al. demonstrated that purified and culture-expanded human 
MSCs could be utilized to improve regeneration in a critical sized femoral defect treated 
with porous hydroxyapatite/beta calcium phosphate scaffolds.79, 80 Stem cell loaded 
constructs exhibited radiological and histological evidence of new bone formation after 8 
weeks with improved biomechanical properties. 
1.4.4.  Natural Polymeric Cell Carriers 
Although MSC delivery holds therapeutic promise, traditional delivery methods (e.g. 
percutaneous grafting of stem cells via syringe or catheter) often result in limited cell 
engraftment and survivability, ranging between 5%-20%.81, 82 In addition, the hostile 
environment of injured or diseased tissue can deprive cells of nutrients or subject them to 
removal by surveilling inflammatory cells, further reducing cell retention. As a result, 
biomaterial carriers that provide an external matrix and mechanical barrier to removal 
have been investigate as an improved substrate for tissue engraftment. Hydrogels, a class 
of biomaterials comprised of hydrophilic, water-swollen polymer networks, have emerged 
as a promising platform for delivering stem cells. Numerous natural and synthetic 
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hydrogels have been investigated for cell encapsulation.83, 84 Natural platforms, such as 
those based on modified gelatin, alginate, or fibrin provide an extracellular-like matrix 
that is both cytocompatible during encapsulation processes, and able to promote cell 
attachment and migration after delivery. Encapsulation in these systems often occurs 
through thermal induced gelation or ionic crosslinking. Awad et al. investigated 
chondrogenic differentiation of adipose derived stem cells encapsulated in multiple natural 
polymer systems including agarose, alginate, and gelatin scaffolds.85 Furthermore, Nichol 
et al. demonstrated that methacrylated gelatin, a natural derivative of collagen, can be 
utilized to encapsulate cells with high cell survival.86 These constructs were advantageous 
as they retained native RGD binding sites and MMP-sensitive degradation sites while 
achieving improved mechanical properties of covalently crosslinked systems.  
1.4.5.  Synthetic Polymeric Cell Carriers 
Synthetic hydrogels, specifically those based on poly(ethylene glycol) (PEG), provide 
an encapsulation platform with excellent cytocompatibility, and a blank slate nature that 
can be modified for any target tissue. Most commonly, hydrophilic precursor solutions are 
fabricated containing prepolymer, photoinitatior, and cell payload. These solutions are 
then exposed to an external UV source to facilitate free-radical polymerization of 
acrylate/methacrylate groups, and physical entrapment of the cell inside the polymer 
network. Excellent encapsulation viability, as well as the ability to promote osteogenic 
differentiation of MSCs was observed by Nuttleman et al.87 After one week, gene 
expression for osteogenic markers osteonectin, ostoeopontin, and alkaline phosphatase 
was upregulated with mineralization present after four weeks. To improve viability of cells 
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encapsulated for extended periods, RGD binding sites have been covalently inserted to 
improve cell-matrix interactions and stimulate bone growth.88, 89 Synthetic hydrogel 
platforms with improved biodegradation have also been explored for cell delivery and 
release. A novel in situ application system based on oligo(poly(ethylene glycol) fumarate) 
was investigated and shown to support osteogenic differentiation of encapsulate rat 
marrow stromal cells.90 The redox initiation mechanism utilized in this system has the 
advantage of not requiring external equipment to facilitate polymerization. This system 
has since been modified to allow for tunable degradation and release of marrow stromal 
cells from the hydrogel cell carrier through incorporation of the hydrolytically degradable 
macromer acrylated poly(ethylene glycol)-dithiothreitol.91 Modulating degradation profile 
was identified as a tool that can be utilized to control cell retention at the tissue site. 
Finally, hydrogel carriers provide the added advantage of being able to simultaneously 
deliver bioactive factors. Simmons et al. demonstrated that bone morphogenetic protein-
2 and transforming growth factor could be combined with stem cell deliver to improve 
ectopic bone formation.92 
1.4.6.  Combination Cell Carriers 
As evidenced by the success of these varied platforms, hydrogel delivery holds strong 
promise in stem cell therapy. A challenge specific to bone tissue engineering is developing 
a cell carrier that has suitable mechanical properties for physiological loading. Recently, 
composite grafts have been investigated to deliver stem cells in more robust scaffolds by 
combining traditional bone grafting materials with hydrogel cell carriers. Zhao et al. 
demonstrated the promise of this approach by encapsulating umbilical cord mesenchymal 
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stem cells in alginate microbeads and incorporating them in an injectable calcium 
phosphate cement paste.93 Encapsulated cells remained viable, exhibited gene markers of 
osteoblastic differentiation, and facilitated mineral synthesis. Similar systems, including 
those based on settable polyurethane scaffolds have been explored with similar promising 
results for chondrogenic tissue repair.94 Combined, this work illustrates the benefits of 
stem cell delivery and the future promise of incorporating these cells in robust scaffold 
design. A primary aim of this work was to expand upon these systems by developing an 
injectable cell carrier that can improve seeding in patient specific grafts prepared with 
state of the art 3D printing modalities. 
1.5.  Growth Factor Delivery in Bone Tissue Engineering 
1.5.1.  Growth Factors in Bone Healing 
As outlined previously in this review, the stages of bone healing are well established. 
What is less established however, is the complex interactions and feedback loops 
regulating these remodeling processes. Although there are physical cues that arise from 
changes in mechanical properties and a loss of nutrient and oxygen supply due to fracture 
and damaged vasculature, the primary initiators of healing are likely the multitude of 
bioactive growth factors released into the fracture site.95 These secreted proteins act as a 
signaling service that directs surrounding cells to carry out a specified action. Upon 
binding of the ligand to a target receptor on the surface of the cell, a conformational change 
occurs, resulting in formation of a transcription factor that travels through the cell. This 
transcription factor then binds nuclear DNA and facilitates new gene expression and 
subsequent morphological changes of the cell. The most prevalent growth factors active 
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in bone repair are summarized in Table 1.2.95, 96 One of the most widely studied of these 
factors are members of the transforming growth factor-beta super family. Signaling from 
these proteins is activated through a transmembrane receptor complex formed by type-I 
and type-II serine/threonine kinase receptors. This leads to downstream activation of class 
of transcription factors known as SMAD proteins, which facilitate the intracellular 
response.97 Other regulating factors such as platelet-drived growth factor initiate response 
through activation of receptor tyrosine kinases.96 Ferguson and colleagues demonstrated 
that the genetic mechanisms that regulate fetal skeletal development also regulate bone 
healing in adults.98 Developing platforms that allow for improved understanding of the 
complex overlap and cross-communication between these signaling pathways has been a 
driving area of study. 
 
 
 
Table 1.2. Role of growth factors in bone repair. 
Factor Activity Source 
Transforming 
growth factor beta 
(TGF-β) 
Stimulate ECM production, 
osteoprogenitor cell 
proliferation, osteogenic 
differentiation 
ECM, platelets, 
inflammatory cells, 
osteoblasts 
Bone 
morphogenetic 
protein (BMP) 
Promote osteoblast and 
chondrocyte differentiation of 
progenitor cells 
ECM, osteoblasts, 
osteoprogenitor cells 
Fibroblast growth 
factor (FGF) 
Mitogenic effect of MSCs, 
osteoblasts and chondrocytes, 
promote angiogenesis 
Macrophages, MSCs, 
chondrocytes, osteoblasts 
Insulin-like growth 
factors (IGF) 
Promote proliferation and 
differentiation of progenitor 
cells 
ECM, chondrocytes, 
osteoblasts 
Platelet-drived 
growth factor 
(PDGF) 
Promote chemotaxis and 
proliferation of macrophages 
and MSCs 
Platelets, osteoblasts, 
macrophages 
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1.5.2.  Bone Morphogenetic Proteins 
The most widely studies proteins studied for bone regeneration are members of a 
subset of the TGF-Beta superfamily known as bone morphogenetic proteins (BMP). 
Investigation into these proteins first began after the discovery that new bone could be 
formed as a result of intramuscular implantation of demineralized bone matrix.99 
Discovery of this ‘bone induction principle’ sparked numerous investigations, eventually 
resulting in the genetic sequencing and identification of numerous bone morphogenetic 
proteins.100 Furthermore, Cheng and colleagues established a hierarchical model of 
osteogenisis for multiple BMPs, observing that BMP-2, -6, and -9 were able to induce 
alkaline phosphatase activity in pluripotent cell lines.101 BMP-2, -4, -6, -7, and -9 were 
able to induce alkaline phosphatase activity in preosteoblasts, while the majority of tested 
factors could induce activity of differentiated osteoblasts. As a result of these collective 
investigations, numerous BMPs have been explored to improve bone regeneration in a 
clinical setting, the most promising of these being BMP-2. The therapeutic effect of BMP-
2 delivery has been shown to emerge from its role in the initiation of fracture healing, 
chemoattactive properties, and facilitation of angiogenesis.13, 102-106 The importance of 
BMP-2 in initiating fracture response is widely recognized as it is present in extracellular 
matrix and released into the wound environment post injury. Tsuji et al. reported that in 
the absence of BMP-2, even in the presence of other osteoindutive stimuli, limb defects in 
a mouse model failed to resolve with time.102 It was critical to note that stem cell 
populations with upregulated expression of BMP receptors were present at the injury site, 
but lacked necessary signaling to facilitate healing. Furthermore, Fiedler et al. reported a 
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greater than 3-fold increase in migration of primary mesenchymal human porogenitor cells 
in response to BMP-2 delivery, suggesting a functional role of BMP-2 factor in the 
recruitment of progenitor cells in bone healing.103 Finally, it has been reported that BMPs 
enhance expression of potent angiogenic factors, including vascular endothelial growth 
factr (VEGF) in osteoblasts.104 This expression is not associated with osteoblastic 
differentiation, but rather serves to combine critical osteogenic and angiogenic processes. 
1.5.3.  Clinically Available Growth Factor Delivery Systems 
Combining bone morphogenetic proteins into grafting materials has been explored as 
an approach to overcoming limitations in autologous bone grafting, to great success. To 
date, two devices have been approved for clinical treatment of bone defects.107-110 Delivery 
of recombinant expressed BMP-2 in an absorbable collagen sponge was first approved for 
treatment of specific interbody spinal fusion procedures. It later gained approval for 
treatment of open tibial fractures in intramedullary nail fixation and most recently for 
specific craniofacial applications. In a 279 patient trial clinical trial for the treatment of 
degenerative disc disease, it was reported that 2-year fusion rates for the BMP/collagen 
sponge were greater than 88%, only marginally lower than autologous rates of 94.5%.108 
No differences in patient pain or neurological profiles were reported. In addition, 
complications related to secondary donor site pain and morbidity were expectedly 
eliminated. Furthermore, use of BMP-7, clinically known as Osteogenic Protein-1, has 
been granted approval by the FDA under the Humanitarian Device Exemption program 
for delivery in a puddy of bovine bone collagen. A clinical trial investigating repair of 
tibial nonunions reported that 75% of patients had radiographic confirmation of fracture 
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healing after nine months, only marginally lower than the autograft treatment at 84%.110 
Despite the clear ability of osteoinductive factor delivery to promote regeneration, several 
safety concerns have emerged. Concerns include inflammation, ectopic bone formation, 
and neurological deficits.111, 112 These undesirable off-target complications often result 
from a bolus release of supraphysiological dosages of the factor. As the majority of protein 
is quickly released form the collagen carrier and removed from the injury site, high 
concentrations of protein are required to be initially loaded to ensure a robust therapeutic 
response.113 These recent complications highlight the need to develop a delivery system 
that can retain the benefits of osteoinductive factor delivery, but limit safety concerns. 
1.5.4.  Controlled Growth Factor Delivery 
Numerous platforms have been investigated to provide controlled release of growth 
factors, aiming to achieve more physiologically relevant delivery profiles. The hydrophilic 
nature and mild fabrication conditions of hydrogels make them intriguing platforms for 
growth factor delivery. Indeed, delivery of BMPs from hydrogel platforms have been 
shown to promote ectopic bone formation. However, to better control release kinetics, 
affinity-based functionality is often required. Furthermore, growth factor delivery in 
calcium phosphate cements has been explored. Limited porosities and poor loading of 
surface coatings limits commercial potential of these systems. As a result, encapsulation 
of growth factors into porous, polymeric microspheres systems has emerged as a method 
to provide controlled release of bioactive factors. 
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1.5.5.  Porous Microspheres for Growth Factor Delivery 
Significant and wide-reaching progress has been made in the development of porous 
microsphere fabrication techniques.114 The most widely studied microsphere platform for 
drug delivery is the fabrication of porous microspheres based on the biodegradable 
polymer pol(lactic-co-glycolide) (PLGA).115, 116 The ester linkages in these polymers 
allow for hydrolytic degradation of the polymer with degradation products that can be 
removed through natural processes. For fabrication, these systems often employ a double 
emulsion-solvent evaporation method. In this method, polymer is first dissolved in a 
volatile solvent, most often methylene chloride or chloroform. The polymer solution is 
then emulsified (water-in-oil) with an aqueous solution containing the protein, added to a 
secondary aqueous phase to form the double emulsion (water-oil-water), and then agitated 
to form the microparticles. The final step is the removal of solvent through excess stirring 
or vacuum drying. To control particle properties like size, emulsion parameters such as 
stirring conditions, solvent choice, and polymer concentration are modulated. Typical 
microsphere diameters fabricated with this method range from 1-200 microns with notable 
size distributions, and pore sizes generally remaining below a single micron.117-119 
Osmotic agents have been utilized to control pore architecture and provide porous systems 
for sustained growth factor release.120 Although exposure to common solvents including 
methylene chloride has demonstrated minimal effect on BMP-2, stability of growth factors 
can vary greatly, and thus compatibility of a method should be determined with caution. 
Other fabrication methods of porous microspheres mirror those used for general 
porous scaffold fabrication. Broadly, these include porogen leaching and gas foaming.121 
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When adapted for microsphere fabrication however, it has proven difficult to adequately 
control the relationship between particle and pore size. Fabrication of porous scaffolds 
through porogen leaching relies on the addition of salts to polymer solutions, followed by 
subsequent leaching of the porogen. This results in heterogeneous pore structures which 
may result in variable scaffold properties. Additionally, the post fabrication requirements 
preclude in-line loading of agents into the scaffolds. Gas foaming has also been explored 
to fabricate porous microsphere by addition of effervescent salts as blowing agents. 
Ammonium bicarbonate has been shown to create highly porous microspheres with pore 
sizes up to twenty microns. In this report however, the relationship between particle size 
and pore size was coupled, limiting the tunability of this system.36  
To minimize manufacturing concerns resulting from costly post fabrication processes, 
including solvent removal and porogen extraction, spray drying has emerged as a minimal 
processing fabrication technique.122 For the encapsulation of proteins, the primary water 
in oil emulsion is sprayed in a stream of heated air. Fabrication parameters of injection 
rate, temperature, and solvent choice are modulated to dictate microsphere morphology. 
Berkland and colleagues demonstrated that coaxial spray drying setups could be utilized 
to fabricate core-shell microspheres with tunable shell thickness.123 Disadvantages of 
spray drying systems include suboptimal yields due to difficulties with microsphere 
collection and potential denaturation if elevated temperatures are utilized for fabrication. 
1.6.  Summary and Approach 
Limited availability of autologous tissue, combined with inherent variability in 
allogenic grafts, is driving the need for an improved bone replacement material. Tissue 
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engineering presents a promising strategy to combine the regenerative advantages of these 
grafts with the availability of synthetic materials. Uniquely, emulsion templating provides 
a platform that can be adapted to generate highly porous scaffolds suitable for bone 
grafting procedure. When designing a tissue engineered polyHIPE graft, it is critical to 
develop a platform that can achieve requisite physical and mechanical properties inside a 
clinical setting. Use of a thiol-methacrylate polyHIPE allows for improved oxygen 
resistance and network formation. Furthermore, the tunable nature of the emulsion 
templating system allows for facile incorporation of injectable carrier, and controlled 
growth factor delivery systems. Combined, these systems provide the tools to develop a 
tissue engineered scaffold capable of actively guiding bone regeneration.  
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CHAPTER II  
THIOL-METHACRYLATE POLYHIPES WITH IMPROVED RESISTANCE TO 
OXYGEN INHIBITION1 
 
2.1. Introduction 
Tissue engineers have demonstrated the importance of biomaterial scaffolds in guiding 
tissue regeneration.124 Ideally, these scaffolds promote neotissue formation by providing 
a 3D substrate to guide cell growth, exhibiting requisite mechanical properties to restore 
function, and degrading at a rate that complements the rate of neotissue formation. A 
variety of fabrication strategies have been employed to achieve this diverse set of criterion 
with differing levels of success.25, 27, 34, 36-39 Emulsion templating is a unique fabrication 
technique that is currently being investigated for application in tissue engineering.125-130 
High internal phase emulsions (HIPEs) are characterized by an internal droplet phase 
volume fraction greater than 74%. Polymerization of the continuous phase secures the 
architecture defined by the emulsion geometry resulting in a high porosity foam 
(polyHIPE). Multiple compositional and processing variables have been investigated to 
determine the effect on emulsion stability and the corollary impact on the resulting pore 
architecture and mechanical properties. Through manipulation of these variables, a diverse 
set of scaffolds have been fabricated with a broad range of pore sizes, porosities, and 
                                                 
1 Part of the data reported in this chapter is reprinted with permission from “Prevention of oxygen inhibition 
of polyHIPE radical polymerization using a thiol-based cross-linker,” by Michael E. Whitely, Jennifer L. 
Robinson, Melissa C. Stuebben, Hannah A. Pearce, Madison A. P. McEnery, and Elizabeth Cosgriff-
Hernandez, ACS Biomaterials Science & Engineering 2017, 3 (3), 409-414. Copyright (2017) American 
Chemical Society. 
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mechanical properties that illustrate the utility of polyHIPEs for hard and soft tissue 
repair.43, 49, 125, 126, 128, 131 
Recently, our lab developed a  polyHIPE scaffold for use as an injectable bone graft 
based on propylene fumarate dimethacrylate (PFDMA).126 Unlike traditional poly(methyl 
methacrylate) bone cements, fumarate based polyHIPEs do not exhibit significant 
exotherms during polymerization and allow for hydrolytic degradation in vivo. Uniquely, 
these injectable grafts cure in situ to compressive properties approaching cancellous bone 
while also promoting osteogenic differentiation of human mesenchymal stem cells.129 No 
previously investigated polyHIPE graft has displayed this combination of properties while 
retaining the requisite properties to permit deployment as a space-filler with in situ cure. 
Although initial in vitro testing of these scaffolds has proved promising, additional criteria 
need to be addressed to permit successful implementation in the clinic. A rapidly curing 
polyHIPE is desired to reduce surgical times, limit infection risk, and rapidly stabilize 
defects.132 We recently reported a redox initiated polymerization route that improved upon 
previous methods of fabricating injectable polyHIPE grafts.128 This system permitted 
fabrication of an off-the-shelf graft with long term storage and cure rates similar to 
commonly used bone cements (<15 minutes) without sacrificing porosity or compressive 
properties.  
The ability to achieve rapid cure with tunable polymerization profiles is a primary 
advantage of our polyHIPE system. However, an injectable polyHIPE for use as a bone 
graft must retain these characteristics when administered in the surgical suite, which 
includes exposure to an oxygen-rich environment. The utilization of radical mediated 
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chain-growth polymerization of methacrylate-capped macromers in our scaffold design 
renders it susceptible to oxygen inhibition. Under oxygen-rich conditions, high levels of 
initiating and propagating radicals are scavenged and converted to peroxy radicals.50, 51 
These peroxy radicals do not readily reinitiate polymerization of vinyl macromers, 
terminating further network formation. This often results in reduced cure rates, elevated 
levels of uncured macromer, and a reduction in mechanical properties.133 Traditional 
industrial methods utilized to prevent oxygen inhibition (e.g. purging with inert gases) are 
not suitable to the proposed application as an injectable graft. Several researchers have 
reported reduced oxygen inhibition in thiol-ene and thiol-acrylate polymerizations. Thiol–
acrylate and thiol-methacrylate polymerization may be initiated via hydrogen abstraction 
from a thiol functional group or radical addition to the acrylate/methacrylate functional 
group. Propagation then proceeds via thiol or methacrylic/acrylic radical addition to 
methacylate/acrylate functional groups.52, 134-136 Unlike vinyl systems where oxygen 
scavenges and effectively terminates radicals, the peroxy radicals generated in the 
presence of oxygen can abstract the thiol hydrogen to generate thiyl radicals that can 
continue to propagate through addition or chain transfer. Thus, the mixed mode initiation 
of the thiol-acrylate /methacrylate polymerizations renders them less susceptible to 
oxygen inhibition. It has been reported that increasing thiol monomer content in diacrylate 
systems resulted in reduced levels of oxygen inhibition.52 Furthermore, higher thiol 
functionality provided a faster polymerization rate and increased viscosity, serving to 
further reduce diffusion of inhibitory oxygen. We hypothesized that the addition of a thiol-
based crosslinker would confer resistance to oxygen inhibition under physiological 
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environments to our injectable polyHIPE system. Although there are previous reports of 
thiol-methacrylate and thiol-ene polyHIPE systems, these were not injectable systems and 
did not characterize the effect of the thiol monomer on oxygen inhibition.137-139  
In addition to achieving requisite physical properties, success in vivo depends on the 
ability of tissue engineered scaffolds to promote recruitment and attachment of native 
osteoprogenitor cells. Attachment of cells to extracellular matrix proteins is mediated 
through a class of heterodimeric surface receptors known as integrins. These linkages play 
critical roles in activate biomechanical and biochemical signaling pathways responsible 
for directing cell activity.140, 141 Unfortunately, synthetic polymeric materials lack these 
native binding sites required for cell attachment, leading to reduced levels of cell 
infiltration in unmodified systems. Furthermore, adsorption of serum proteins from media 
has been shown to be heterogenous and substrate dependent during in vitro testing.142 To 
combat this lack of native binding, hybrid systems containing natural polymers have been 
explored as surface modifiers in tissue engineered systems.143, 144 Specifically, gelatin, a 
derivative of naturally produced collagen, has been widely utilized to develop scaffolds 
with improved substrates for cell adhesion and proliferation.86, 131 An injectable polyHIPE 
that combined the cell attachment advantages of natural polymers with the physical and 
mechanical properties of fumarate based polyHIPEs would prove a promising option in 
bone grafting procedures.  
In this study, we explore the use of a tetrafunctional thiol, pentaerythritol tetrakis(3-
mercaptoproprionate (tetrathiol), to provide improved resistance to oxygen inhibition to 
injectable PFDMA polyHIPEs. Rheological properties were monitored to determine the 
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effect of thiol on crosslinking kinetics by characterizing work and set times. To further 
probe this relationship, gel fraction was quantified to assess the impact of tetrathiol 
incorporation on network formation under ambient and inert conditions. To evaluate the 
potential of our system in orthopaedic applications, the effects of tetrathiol concentration 
on pore architecture, compressive modulus, and yield strength were assessed. Thiol based 
scaffolds have previously demonstrated improved degradation rates in vivo and could 
prove a potent method for tuning polyHIPE degradation. To this end, the effect of thiol 
incorporation on hydrolytic degradation rate was determined by measuring mass loss after 
accelerated hydrolytic testing. Next, human mesenchymal stem cell (hMSC) activity and 
scaffold-induced osteogenic differentiation were investigated using established viability, 
proliferation, and alkaline phosphatase (ALP) assays. Finally, polyHIPE scaffolds were 
modified with functionalized gelatin to characterize improvements in cell attachment, 
viability, and spreading in surface modified grafts. This work aims to highlight the strong 
potential of thiol-methacrylate polyHIPEs to serve as rapid-curing injectable bone grafts 
that retain desirable properties when applied under physiological conditions.  
2.2. Materials and Methods 
2.2.1. Materials 
Polyglycerol polyricinoleate (PGPR 4125) was donated by Palsgaard. Human 
mesenchymal stem cells were provided by the Texas A&M Health Science Center College 
of Medicine Institute for Regenerative Medicine at Scott & White. All other chemicals 
were purchased and used as received from Sigma–Aldrich, unless otherwise noted.  
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2.2.2. PFDMA Synthesis and Purification 
Propylene fumarate dimethacrylate (PFDMA) was synthesized in a two-step process 
adapted from Timmer et al 145. Briefly, propylene oxide was added dropwise to a solution 
of fumaric acid and pyridine in 2-butanone (2.3:1.0:0.033 mol) and refluxed at 75°C for 
18 hours. Residual propylene oxide and 2-butanone were removed through a two-step 
distillation procedure. Residual acidic by-products and water were removed with washing, 
and the product was dried under vacuum (<0.2 millibar) at ambient temperature for 12 
hours. The diester bis(1,2 hydroxypropyl) fumarate product was then end-capped with 
methacrylate groups using methacryloyl chloride in the presence of triethylamine. The 
molar ratios of the diester, methacryloyl chloride, and triethylamine were 1:2.1:2.1, 
respectively. Hydroquinone was added at a molar ratio of 0.008:1 to inhibit crosslinking 
during synthesis. The reaction was maintained below -10˚C to reduce undesirable side 
reactions and stirred vigorously overnight under a nitrogen blanket. The macromer was 
neutralized overnight with 2 M potassium carbonate and residual base removed with an 
aluminum oxide column (7 Al2O3:1 TEA). The PFDMA product was then vacuum dried 
and the structure confirmed using 1H NMR (300 MHz, CdCl3), δ 1.33 (dd, 3H, CH3), 1.92 
(s, 3H, CH3), 4.20 (m, 2H, -CH2-), 5.30 (m, 1H, -CH-), 5.58 (s, 1H, -C=CH2), 6.10 (s, 
1H, -C=CH2), 6.84 (m, 2H, -CH=CH-). The integration ratio of methacrylate protons to 
fumarate protons in the 1H NMR spectra was used to confirm > 90% functionalization 
prior to polyHIPE fabrication. 
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2.2.3. PolyHIPE Fabrication 
HIPEs were prepared using a FlackTek Speedmixer DAC 150 FVZ-K following a 
method adapted from Moglia et al.128 Briefly, PFDMA was mixed with a varied amount 
of pentaerythritol tetrakis(3-mercaptoproprionate) (0, 5, or 10 mol%) and 200 PPM 
hydroquinone as inhibitor, Figure 2.1. Two mixtures containing either 1 wt% benzoyl 
peroxide as initiator or 1 wt% trimethylaniline as reducing agent were combined with the 
organic phase and 10 wt% PGPR prior to emulsification. After homogenous mixing of the 
organic phase, an aqueous solution of calcium chloride (1 wt%) was added to the organic 
phase (75% v) in six additions and mixed at 500 rpm for 2.5 min. HIPEs were placed into 
a double barrel syringe and the two components mixed upon injection using a static mixing 
head into centrifuge tubes (5 mL syringe with 3 cm straight mixer, Sulzer Mixpac K-
System). HIPEs were placed in a 37°C aluminum bead bath to facilitate crosslinking 
overnight. 
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Figure 2.1. Molecular structure of propylene fumarate dimethacrylate (PFDMA) (A) 
and pentaerythritol tetrakis(3-mercaptoproprionate) (tetrathiol)  (B). Reprinted from 
Whitely et al.146 
 
 
 
2.2.4. Rheological Analysis 
Work and set times of the polyHIPEs were characterized using an Anton Paar MCR 
301 rheometer following a procedure adapted from Foudazi et al.147 Storage and loss 
moduli were measured every 15 seconds using a parallel-plate configuration with a 1 mm 
gap and 0.5% strain. Redox initiated HIPEs were injected through a mixing head onto the 
plate heated to 37ºC. Work time was determined as the onset of storage modulus increases 
and set time determined as the tan δ minimum, which corresponds to the yielding of 
storage modulus. Values were reported as the average of three specimens from three 
different HIPEs for each composition (n = 9).   
2.2.5. Gel Fraction and Sol Fraction Composition 
Gel fraction was quantified to assess the impact of tetrathiol incorporation on network 
formation under ambient and inert conditions. Two distinct polyHIPE specimen 
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morphologies were utilized to investigate the extent of oxygen inhibition during 
polymerization. To characterize network formation at the scaffold surface, polyHIPEs 
were cured into a bead morphology with a high surface-area-to-volume ratio under 
ambient conditions. Scaffolds were also cured in the same morphology under a nitrogen 
blanket to confirm inhibition by oxygen (Labconco Controlled Atmosphere Glovebox). 
To characterize network formation under bulk-cured conditions, polyHIPEs were cured 
into 15 mL centrifuge tubes and sectioned 1 mm thick from the polyHIPE bulk (Isomet® 
saw). All specimens were vacuum dried for 48 hours, weighed, and then extracted in 
dichloromethane (DCM) at a ratio of 1 mL DCM to 10 mg of specimen to facilitate 
dissolution of uncrosslinked macromer. After extraction on a shaker table for 48 hours, 
the DCM was decanted and the specimens vacuum dried for 48 hours at ambient 
temperature. The gel fraction was calculated as the final weight divided by original weight 
(n = 6). The fraction of mass loss attributed to surfactant was subtracted prior to gel 
fraction calculation. The extractables of high surface area bead constructs cured under 
ambient conditions were analyzed with 1H NMR (300 MHz, CdCl3) after vacuum removal 
of the DCM from the sol fraction. The integration ratio of the PFDMA methacrylate 
protons to tetramethylsilane protons in the 1H NMR spectra was used to identify 
qualitative differences in residual monomer content present in 0 and 10 mol% thiol-
methacrylate polyHIPEs. 
2.2.6. Scaffold Architecture Characterization 
Average polyHIPE pore size was determined using scanning electron microscopy 
(SEM, Phenom Pro, Nanoscience Instruments). Specimens from three separate polyHIPEs 
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were vacuum dried for 24 hours to remove water, sectioned into disks, and fractured at the 
center to produce an unaltered surface for characterization. Each specimen was coated 
with gold and imaged in a raster pattern yielding five images. Pore size measurements 
were completed on the first ten pores that crossed the median of each 1000x magnification 
micrograph. Average pore sizes for each polyHIPE composition were reported (n = 150). 
A statistical correction was calculated to account for the random fracture plane through 
spherical voids and pores, 2/ .148 Average diameter values were multiplied by this 
correction factor to yield a more accurate pore diameter description.  
2.2.7. Compressive Testing  
The effect of thiol concentration on polyHIPE compressive modulus and yield strength 
was investigated following ASTM D1621-04a. PolyHIPEs were cured in 15 ml centrifuge 
tubes and sectioned into disks with a 3:1 diameter to height ratio (15 mm diameter, 5 mm 
thick) using an Isomet® saw. PolyHIPE specimens were compressed using an Instron 
3300 at a strain rate of 50 mm/s. The compressive modulus was calculated from the slope 
of the linear region and the compressive strength was identified, after correcting for zero 
strain, as the stress at the yield point or 10% strain, whichever point occurred first. 
Reported compressive moduli and yield strength data were averages of nine specimens for 
each polyHIPE composition. 
2.2.8. Accelerated Degradation In Vitro 
Accelerated degradation testing was performed on polyHIPE specimens that were 
sectioned using an Isomet® saw into 1 mm thick sections. Specimens were vacuum dried 
for 48 hours and dry weights recorded prior to incubation in base solution (0.25 and 0.5M 
3
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NaOH) at a ratio of 1 g specimen to 20 mL solution. Specimens were secured with Teflon 
weights in the solution and placed on a shaker table at 37°C. The solutions were changed 
every 2-3 days with time points every week for four weeks. At each time point, specimens 
were washed twice with RO water, incubated for 1 hour with 1 mL RO water to remove 
any salts and dried under vacuum for 48 hours before weighing (n = 3).   
2.2.9. Culture of Human Mesenchymal Stem Cells 
Bone marrow-derived hMSCs were obtained as passage 1 from the Center for the 
Preparation and Distribution of Adult Stem Cells at Texas A&M Health Science Center 
College of Medicine, Institute for Regenerative Medicine at Scott & White through NIH 
Grant # P40RR017447. Cells were cultured to 80% confluency on tissue-culture 
polystyrene flasks in standard growth media containing Minimum Essential Media α 
(MEM α, Life Technologies) supplemented with 16.5% fetal bovine serum (FBS, Atlanta 
Biologicals) and 1% L-glutamine (Life Technologies) prior to passaging. All experiments 
were performed with cells at passage 3.  
2.2.10. Cytocompatibility of Leachable Components from PolyHIPEs 
A viability study was performed to assess the cytocompatibility of the extractables 
from cross-linked polyHIPE networks immediately following scaffold injection and cure. 
PolyHIPEs containing 0 or 10 mol% tetrathiol were cured into a bead morphology with a 
high surface-area-to-volume ratio under ambient conditions and incubated in standard 
growth media at 37°C at a ratio of 0.13 mL HIPE to 1 mL media (surface area ~975 
cm2/mL). After 24 hours, the extraction media was collected and sterile filtered. To 
approximate the extractables from bulk-cured specimens that have roughly 50% of the sol 
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fraction of the bead specimens, extracts were diluted to 0.5 vol% with media. hMSCs were 
seeded at a density of 40,000 cells/cm2 in a 96-well plate and allowed to adhere for 24 
hours prior to extract exposure. 100 µL of the extract solutions was added to hMSCs and 
the cells cultured for 24 hours. Viability was assessed utilizing the LIVE/DEAD assay kit 
(Molecular Probes) according to standard protocols. Briefly, cells were washed with PBS, 
stained with 2 µM calcein-AM (live) and 2 µM ethidium homodimer-1 (dead) for 30 
minutes at 37°C, and washed with PBS for imaging. Imaging (3 images per specimen) 
was conducted on five specimens (n = 15) with a fluorescence microscope (Nikon Eclipse 
TE2000-S). 
2.2.11. hMSC Viability on Thiol-Methacrylate PolyHIPEs 
Investigation of hMSC viability and morphology on seeded constructs was performed 
to assess the effect of tetrathiol addition on cell behavior. PolyHIPEs were fabricated 
utilizing 0 or 10 mol% tetrathiol and sectioned into 500 µm thick wafers using an Isomet® 
saw. Specimens were sterilized for 3 hours in 70% ethanol, subjected to a progressive 
wetting ladder, washed four times with PBS, and incubated overnight in MEM α 
supplemented with 40 w/v% FBS at 5% CO2, 37°C. hMSCs were seeded at a density of 
50,000 cells/cm2 onto the polyHIPE sections.  Viability at 24 hours, 72 hours, and 1 week 
was assessed utilizing the LIVE/DEAD assay kit (Molecular Probes). Cells were washed 
with PBS, stained with 2 µM calcein-AM (live) and 2 µM ethidium homodimer-1 (dead) 
for 30 minutes at 37°C, and washed with PBS for imaging. Imaging (3 images per 
specimen) was conducted on five specimens (n = 15) with a fluorescence microscope 
(Nikon Eclipse TE2000-S).  
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2.2.12. hMSC Proliferation on Thiol-Methacrylate PolyHIPEs 
A Quant-iT™ PicoGreen® dsDNA Assay Kit (Molecular Probes) was utilized to 
quantify dsDNA to confirm thiol-methacrylate polyHIPEs supported hMSC proliferation. 
hMSCs were seeded at a density of 50,000 cells/cm2  in standard growth media and 
allowed to adhere. After 24 hours, growth media or osteogenic media (growth media 
supplemented with 50 μg/mL ascorbic acid, 10 mM β-glycerophosphate, and 10 nM 
dexamethasone) was added and changed every 2 days for 10 additional days. PolyHIPE 
sections were removed from the culture wells and placed in unused wells for the lysis 
procedure prior to the PicoGreen assay to ensure only DNA from cells adhered to the 
scaffolds was measured. The assay was performed according to manufacturer instructions 
and fluorescence intensity was assessed using a plate reader (Tecan Infinite M200Pro) 
with excitation/emission wavelengths of 480/520 nm, respectively. Average cell number 
for day 1, 6, and 11 was determined by converting dsDNA values to individual cell number 
using 6.9 pg DNA/cell.149 Specimens were analyzed in triplicate. 
2.2.13. Alkaline Phosphatase Activity of hMSCs on Thiol-Methacrylate PolyHIPEs 
Alkaline phosphatase activity of cells cultured on polyHIPE scaffolds was determined 
by monitoring the conversion of p-nitrophenyl phosphate (PNPP, Thermo Scientific) to p-
nitrophenol. hMSCs were seeded at a density of 50,000 cells/cm2  in standard growth 
media and allowed to adhere. After 24 hours, growth media or osteogenic media (growth 
media supplemented with 50 μg/mL ascorbic acid, 10 mM β-glycerophosphate, and 10 nM 
dexamethasone) was added and changed every 2 days for 10 additional days following 
measurement of ALP activity. Scaffold cultures were washed with ALP reaction buffer 
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(100 mM Tris-HCl, pH 9, containing 100 mM KCl and 1 mM MgCl2) and incubated with 
pNPP for 30 min. ALP activity was determined as the rate of PNPP conversion to p-
nitrophenyl by measuring the absorbance at 405 nm (Tecan Infinite M200Pro) and 
normalized to cell number obtained from the PicoGreen assay. Specimens were analyzed 
in triplicate. 
2.2.14. Surface Modification of PolyHIPE Scaffolds 
Methacrylated gelatin was synthesized by adding 2-isocyantoethyl methacrylate 
(IEMA) to a 2.5% (w/v) gelatin solution in dimethyl sulfoxide. The reaction was allowed 
to proceed under stirred conditions for 3 h at 40 °C. The fraction of lysine groups was 
reacted at a 1x ratio with IEMA under the assumption of 11 lysines per protein molecule. 
After completion, the solution was dialyzed against distilled water for 24 hours at 40 °C 
to remove impurities and lyophilized. Functionalized gelatin was added as the aqueous 
phase of the model HIPE (1, 4 butanediol dimethacrylate) at a 2 wt% solution and mixed 
using standard fabrication methods. The collagen indicator, picrosirius red (PSR), was 
used to confirm attachment of gelatin to the scaffold surface after polymerization and 
sterilization. Scaffolds were stained with a 1 mg/mL solution for 30 min at room 
temperature. After staining, scaffolds were rinsed with deionized water 5× and digitally 
photographed. 
2.2.15. hMSC Attachment on Gelatin Modified PolyHIPEs 
The impact of polyHIPE surface modification on cellular behavior was determined by 
characterizing adhesion, spreading, and viability of hMSCs a 24 hours. Gelatin modified 
scaffolds were prepared and sterilized as described previously. hMSCs were seeded at a 
 39 
 
density of 10,000 cells/cm2 onto polyHIPE sections.  Viability and spreading was assessed 
utilizing the LIVE/DEAD assay and imaging protocols outlined previously. Attachment 
of hMSCs was quantified using ImageJ analysis on viability stained images. 
2.2.16. Pilot Assessment of PolyHIPE Biocompatibility 
In vivo deployment procedures and initial biocompatibility of injectable PFDMA 
HIPEs was assessed in a critical sized rat calvarial defect adapted from Spicer et al. 
Briefly, an incision was made through outer tissue layers of the scalp and an 8 mm 
craniotomy made using a dental drilling machine with an 8 mm trephine burr. The 
resulting defect was cleaned prior to the addition of the HIPE from a double-barrel syringe. 
HIPE was allowed to cure for 2 minutes, followed by suturing of the periosteum, 
subcutaneous tissue, and skin. Histological analysis was performed after 4 weeks to 
characterize preliminary host response. Integration of thiol-methacrylate polyHIPEs with 
native bone tissue was assessed using a rabbit medial femoral condyle defect with 
diameter 3.5 mm and depth of 5 mm. Femur specimens with polymerized polyHIPE were 
harvested, sectioned utilizing a low speed Isomet® saw and imaged utilizing a scanning 
electron microscope (SEM) (JEOL 6500). 
2.2.17. Statistical Analysis  
The data are displayed as mean ± standard deviation for each composition. A Student’s 
t-test was performed to determine any statistically significant differences between 
compositions. All tests were carried out at a 95% confidence interval (p<0.05). 
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2.3. Results and Discussion 
2.3.1. Effect of Tetrathiol Concentration on PolyHIPE Fabrication and Architecture 
Given that successful polyHIPE fabrication is dependent on characteristics such as 
macromer hydrophobicity and viscosity, the effect of the thiol additive on emulsion 
stability was first assessed. The octanol-water partition coefficient (logP) was used as a 
means of comparing molecular hydrophobicity. LogP values are a measure of the 
differential solubility of a compound between two immiscible solvents, typically water 
and a hydrophobic solvent such as octanol. LogP values range from 0-20 where 0 
corresponds to a hydrophilic molecule and 20 a hydrophobic molecule. The tetrathiol has 
a logP of 1.0 and a viscosity of 0.41 Pa.s compared to PFDMA with a logP of 3.4 and 0.13 
Pa.s viscosity. Despite these differences in molecular hydrophobicity and viscosity, all 
compositions formed stable HIPEs and cured to rigid, interconnected monoliths. Pore size 
and homogeneity have been used as a relative measure of HIPE stability and strongly 
influence the monolith compressive properties and cellular behavior. The addition of the 
tetrathiol had a negligible effect on polyHIPE pore architecture, Figure 2.2. Likely, the 
low concentration of tetrathiol in the organic phase and rapid cure of the PFDMA HIPE 
limited time for phase separation and resulting effects on polyHIPE architecture. Retention 
of the desired pore architecture permits investigation of these polyHIPEs as scaffolds with 
reduced oxygen inhibition. 
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Figure 2.2. Representative scanning electron microscopy (SEM) micrographs of 
PFDMA (A), PFDMA-5T (B), and PFDMA-10T (C) polyHIPE pore architecture. 
Reprinted from Whitely et al.146 
 
 
 
2.3.2. Effect of Tetrathiol Concentration on PolyHIPE Cure Rate 
Developing a material with polymerization kinetics comparable to commonly utilized 
bone cements is critical to successful translation of our device. In general, the work time 
of dental cements is defined by ISO 9917 as the time at which a physician can manipulate 
and inject the graft without altering any material properties. The set time is the point at 
which the material has reached its gelation point and the network is set. According to ISO 
5833, acrylic based cements should have a set time of 10-15 minutes. PolyHIPE cure rates 
were determined utilizing rheological methods with the onset and yielding of the storage 
modulus defined as the work and set times, respectively. PFDMA polyHIPE work and set 
times decreased with the addition of tetrathiol, Figure 2.3. The ~1.5 minute work time of 
PFDMA was reduced to 15 seconds with the addition of either 5 or 10 mol% tetrathiol. 
Similar trends were observed with the set time of these polyHIPEs. No significant 
difference in work and set times were observed between thiol concentrations utilizing this 
method. It was hypothesized that the extent of oxygen consumption needed prior to 
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initiation provided the increased cure time of the PFDMA polyHIPE control. Increased 
induction time in the presence of inhibitory oxygen has been well documented in other 
vinyl mediated systems.150 It has been reported that the equilibrium dissolved oxygen in 
acrylate systems is ~10-3 M.51, 151 Decker et al. reported that the dissolved oxygen 
concentration in these systems must decrease by a factor of 300 to ~4 x 10-6 M prior to 
polymerization proceeding.51 It was hypothesized that the addition of the thiol-based 
crosslinker permitted a reduced induction period and rapid network formation under 
ambient conditions due to the mixed mode chain and step growth polymerization 
mechanism of the thiol-methacrylate HIPEs. In addition to the increase in methacrylate 
polymerization rate with the addition of the thiol, the delay in methacrylate 
homopolymerization due to oxygen inhibition is minimized because the peroxy radicals 
can abstract the thiol hydrogen to generate thiyl radicals that can continue to propagate 
through addition or chain transfer.152 Although the presented set times are approximately 
10X faster than current bone cement standard values, the cure times can be modulated by 
decreasing redox initiator concentration, initiator and reducing agent ratios, and 
chemistries, as shown previously.128  
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Figure 2.3. Storage modulus during polymerization of polyHIPE (A) and work and set 
times (B) of polyHIPEs cured at 37 °C with 1.0 wt% initiator and reducing agent. 
Reprinted from Whitely et al.146 
 
 
 
2.3.3. Improved Resistance to Oxygen Inhibition in PolyHIPE Scaffolds 
The inhibitory effect of molecular oxygen on the polymerization of multifunctional 
monomers has been widely acknowledged as a primary limitation in traditional free-
radical polymerization.150, 153, 154 Several methods have been explored to overcome this 
limitation including the use of elevated concentrations of initiating agents, high-intensity 
irradiation sources, and fabrication within an inert environment.155, 156 However, less 
progress has been made in addressing this limitation in an injectable system intended for 
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in situ polymerization. The primary aim of this work was to fabricate an injectable, 
polyHIPE bone graft that could provide more rapid and complete network formation in a 
clinically relevant environment. Specifically, we aimed to better understand the effect of 
oxygen inhibition on network formation in our polyHIPE system.  
A major advantage of the emulsion templating platform is the ability to readily 
modulate pore architecture and surface area, properties vital to the success of tissue 
engineered scaffolds.157 A range of surface areas have been reported from 3-20 m2g-1  for 
traditional polyHIPEs to greater than 700 m2g-1 for porogen modification scaffolds.158, 159 
Although promising for promoting cell activity, the increased surface area of polyHIPEs 
provides a challenge over non-porous systems as it allows for increased diffusion of 
inhibitory oxygen into the HIPE surface. Near-complete network formation at these 
surfaces is critical to establishing suitable integration with native tissue and providing 
proper mechanical support. In order to better approximate monomer incorporation at the 
outer surface of the HIPE, network formation was first characterized in polyHIPEs cured 
in a high surface area morphology (flat bead) that maximized exposure to ambient oxygen. 
It was expected that the outer polyHIPE surface would be unable to compensate for the 
continual diffusion of oxygen into the sample and experience severely reduced 
polymerization and increased surface tackiness. Gel fraction was reduced to 38% in 
PFDMA control polyHIPEs cured under ambient conditions, Figure 2.4A. It follows that 
in the absence of inhibitory oxygen, monomer conversion in vinyl systems should increase 
to levels comparable to those of their oxygen resistant analogues. To this end, network 
formation was characterized in polyHIPEs cured under an inert nitrogen blanket in the 
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high surface area morphology. PFDMA polyHIPE gel fraction increased to 60%, 
confirming the inhibitory effect of oxygen on our system. It is established that 
incorporation of thiol monomers mitigates the effects of oxygen exposure by acting as 
chain transfer agents and restoring initiating thiyl radicals. As expected, the addition of 5 
and 10 mol% tetrathiol improved network formation to greater than 60% and 70% when 
cured under ambient conditions. It was hypothesized that the increase in continuous phase 
viscosity provided by tetrathiol addition further served to improve inhibition resistance by 
decreasing oxygen diffusion into the scaffold. The effect of monomer viscosity in reducing 
oxygen inhibition has been studied in other thiol-acrylate systems.52, 160 Furthermore, 
network formation in thiol-methacrylate polyHIPEs increased to a lesser extent when 
cured under inert conditions as compared to PFDMA polyHIPE controls. Differences in 
network formation between methacrylate and thiol-methacrylate scaffolds cured under 
nitrogen-purged conditions was attributed to the presence of small amounts of residual 
oxygen.  
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Figure 2.4. The effect of increasing tetrathiol concentration on average gel fraction for 
high surface-area-to-volume ratio polyHIPEs cured under ambient and low oxygen 
conditions (A) and bulk cured polyHIPEs cured under ambient conditions (B). Reprinted 
from Whitely et al.146 
 
 
 
Oxygen inhibition has also been modeled in acrylate systems to identify the effect of 
film thickness on oxygen inhibition.136 It is accepted that as film thickness increases, 
inhibitory oxygen levels decrease and allow for polymerization. The subsequent increase 
in viscosity during cure serves to limit subsequent diffusion of oxygen. Therefore, it was 
expected that network formation of PFDMA monomers in bulk-cured scaffolds would be 
comparable to thiol-methacrylate systems. Gel fraction values were 85% for PFDMA 
controls, 87% for 5 mol% tetrathiol, and 92% for 10 mol% tetrathiol, Figure 2.4B. 
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Observed increases in gel fraction for thiol-methacrylate polyHIPEs under these 
conditions was attributed to the presence of dissolved oxygen prior to cure. Previous work 
has demonstrated injectable, fumarate based systems with sol fraction values greater than 
10% to be biocompatible and support new bone formation in vitro and in vivo.161-163 
Furthermore, commercially available bone cements have been shown to exhibit site 
specific network formation within the implant site.164 Our ability to improve network 
formation in the presence of oxygen, combined with the success of similar fumarate 
systems, illustrates the strong clinical potential of these polyHIPE bone grafts. 
2.3.4. Improved Storage Stability with Hydroquinone Additive  
We have previously demonstrated that redox initiated polyHIPEs have the ability to 
be stored for extended periods and serve as an off-the-shelf graft. Although thiol-
methacrylate polyHIPEs demonstrated improved resistance to oxygen inhibition, an 
increase in emulsion viscosity that precluded proper injection and space filling was 
observed after only one week of storage. It has been reported that thiol monomers may act 
as a primary reducing agent and yield high monomer conversion rates in redox initiated 
thiol-ene systems.165 It was hypothesized that the loss of storage stability in our system 
resulted from the uninhibited reaction of benzoyl peroxide with the tetrathiol monomer 
during fabrication and storage. This allowed marginal levels of initiating radicals to form 
prior to mixing, facilitate early crosslinking, and increase emulsion viscosity. This high 
reactivity of thiol-ene systems often prompts the need for additional stabilizing agents to 
prevent undesired polymerization.134, 166 To this end, hydroquinone was added as a 
stabilizing agent to the HIPE to scavenge propagating radicals and prevent early 
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polymerization, Figure 2.5A. Quinone based inhibitors have been utilized to control the 
induction period and polymerization rate of thiol-ene polymerizations initiated with 
benzoyl peroxide.165  Inhibitor concentration of 200 PPM was selected as the lowest 
concentration required to prevent early polymerization while retaining a reduced 
activation profile to allow rapid cure during redox initiation. Storage time of stabilized 
polyHIPEs with 10 mol% tetrathiol was monitored for 30 days to ensure an increase in 
storage time. Cure rate and gel fraction of stabilzed polyHIPEs was characterized to ensure 
the addition of inhibitor did not negatively impact key scaffold properties. Although a 
minimal decrease in cure rate and gel fraction was observed in stabilized polyHIPEs as 
compared to non-stabilized controls, the values still provide a marked increase over 
PFDMA only and support significant resistance to oxygen inhibition, Figure 2.5.  
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Figure 2.5. The effect of hydroquinone inhibitor (A) on average storage time (B), work 
and set time (C), and gel fraction (D) of thiol-methacrylate polyHIPEs. Reprinted from 
Whitely et al.146 
 
 
 
2.3.5. Retention of Compressive Properties 
PFDMA/tetrathiol polyHIPE compressive modulus and yield strength were assessed 
to ensure that these polyHIPEs retained appropriate compressive mechanical properties 
for use as bone grafting materials. A significant decrease in compressive modulus and 
yield strength was observed with an increase in tetrathiol concentration, Figure 2.6. 
PFDMA polyHIPEs fabricated with greater than 10 mol% tetrathiol exhibited decreases 
in compressive properties greater than 40% as compared to PFDMA controls and were 
not further characterized. PFDMA polyHIPEs with 10 mol% tetrathiol resulted in an 
average compressive modulus of 15 MPa and strength of 0.7 MPa. It was hypothesized 
that the observed decrease in compressive properties was due to a reduction in crosslink 
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density. Increasing the number of thiol functional groups resulted in an increase in chain 
transfer during polymerization with a resulting reduction in chain length and the number 
of crosslinks attached to each kinetic chain. A similar decrease in compressive modulus 
with increasing amount of trithiol was observed by Rydholm et al. in poly(ethylene 
glycol)-based hydrogels.152 
 
 
 
 
Figure 2.6. The effect of increasing tetrathiol concentration on polyHIPE compressive 
modulus (A) and yield strength (B). Reprinted from Whitely et al.146 
 
 
 
Although there was a reduction in compressive modulus and yield strength, the values 
were still within the range of typical bone grafting materials. The ability to promote new 
bone formation within porous and biodegradable systems has been reported with scaffold 
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compressive moduli ranging from 2-100 MPa.167-170 Introduction of porosity into these 
systems is often achieved through particulate leaching or gas foaming, techniques that 
may result in reduced compressive properties as porosity is increased.171-174 In contrast, 
emulsion templating yields a uniform and spherical pore architecture that eliminates the 
potential for stress concentrators. As a result, PFDMA and thiol-methacrylate polyHIPEs 
exhibit improved mechanical properties over similar systems of >70% porosity, and retain 
compressive properties within a range demonstrated suitable in vivo.171, 172 Recent work 
has focused on incorporating additional methacrylate-functionalized monomers into the 
HIPE organic phase to further modulate viscosity for cell encapsulation. PolyHIPEs 
fabricated from these monomers alone have increased crosslink density and therefore 
increased compressive properties. As a result, it is probable that modulating the molar 
ratio of PFDMA:methacrylated-monomer will result in an increase in compressive 
properties relative to standard PFDMA polyHIPEs. 
2.3.6. Tunable Degradation Profiles 
An additional goal of fabricating thiol-methacrylate polyHIPEs was to generate 
scaffolds with a tunable degradation profile for future matching with in vivo neotissue 
formation. Thiol-methacrylate scaffolds with tunable degradation profiles have previously 
shown promise for use as tissue engineered scaffolds. Accelerated degradation scouting 
studies were conducted at two sodium hydroxide concentrations (0.25 and 0.5 M NaOH) 
to determine the effect of tetrathiol on PFDMA polyHIPE degradation. Values reported 
reflect mass loss after accounting for the theoretical mass of the surfactant, PGPR. An 
increase in mass loss was observed with an increase in tetrathiol concentration when 
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assessed in basic, accelerated conditions, Figure 2.7. In 0.5 M NaOH conditions, all thiol-
methacrylate polyHIPEs exhibited complete loss of integrity by 3 weeks whereas the 
PFDMA polyHIPE control maintained ~35% mass loss after the initial mass loss at 1 
week. The initial PFDMA mass loss at one week was attributed to the removal of 
unreacted macromer or the formation of rapidly degrading microgels, which was further 
supported with the lower gel fraction of PFDMA control polyHIPEs.175 This increase in 
hydrolytic degradation rate of thiol-methacrylate polyHIPEs was attributed to the 
incorporation of β-thioesters and reduction in crosslink density due to increased chain 
transfer.176 Schoenmaker et al. demonstrated an increase in atomic charge on the carbon 
atom of an ester as the distance from the sulfide decreased rendering it more susceptible 
to hydrolytic attack. It is believed that the increased number of hydrolytically labile ester 
linkages present in the fumarate backbone of PFDMA would allow for increased 
degradation over similar methacrylate monomers without requiring increased thiol 
content. Although an increase in degradation rate was observed in vitro, the in vivo 
degradation rate of these specific polyHIPE formulations is unknown and would need to 
be explored in an animal model. Degradation and cytocompatibility profiles of similar 
fumarate based systems have been previously reported in in vitro and in vivo models.177-
179  
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Figure 2.7. The effect of increasing tetrathiol concentration on polyHIPE degradation up 
to 4 weeks in 0.25 M NaOH (A) and 0.5 M NaOH (B). Reprinted from Whitely et al.146 
 
 
 
2.3.7. Osteogenic Activity Supported on Thiol-Methacrylate PolyHIPEs 
A primary aim in bone tissue engineering is the development of scaffolds that allow 
for the recruitment and retention of stem cell populations at the site of injury. Therefore, 
a main goal of this work was to create a highly porous, oxygen resistant bone graft that 
would support desired cellular activity through verification of viability, proliferation and 
osteogenic activity of hMSCs. Studies with poly(propylene fumarate)-based biomaterial 
scaffolds with similar chemistries demonstrated in vitro cytocompatibility and in vivo 
biocompatibility illustrating the potential of PFDMA based systems.39, 167, 180 Furthermore, 
our lab previously demonstrated PFDMA polyHIPEs are capable of supporting hMSC 
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viability up to 2 weeks.128 Given the proposed application of polyHIPEs to be injected and 
cured in situ, an extraction study was performed on cross-linked PFDMA control and 10 
mol% thiol-methacrylate scaffolds to provide an initial assessment of the 
cytocompatibility of the injectable polyHIPE immediately following cure. Although acute 
viability of hMSCs exposed to undiluted extraction media of polyHIPE bead specimens 
was poor (<30%), a significant improvement in acute viability and morphology was 
observed for the thiol-methacrylate polyHIPEs at 0.5 vol% over the PFDMA control. 
Viability increased to greater than 94%, with no morphological differences observed 
between hMSCs cultured with the thiol-methacrylate extract compared to standard growth 
media, Figure 2.8. The bead morphology was used to provide high surface-area-to-
volume ratios that would maximize the effect of oxygen inhibition and sol fraction. The 
2X dilution of the extraction solution was used to estimate extractable concentrations of 
bulk polymerized specimens (roughly 50% sol fraction of bead specimens, Figure 2.4), 
which are expected to be more similar to bone grafting applications. It was hypothesized 
that the improvement in network formation in thiol-methacrylate systems reduced 
leachable monomer content present in the extraction media and resulted in improved 
viability over the PFDMA control. Figure 2.9, illustrates a decrease in PFDMA macromer 
content present in extraction media as determined by 1H NMR.  
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Figure 2.8. hMSC viability after 24 h incubation with two concentrations of PFDMA 
and PFDMA-10T extracts (1.0 and 0.5 vol%) (A). Micrographs illustrating live (green) 
and dead (red) cells cultured with respective polyHIPE extracts at 0.5 vol% (B). 
Reprinted from Whitely et al.146 
 
 
 
 
Figure 2.9. NMR spectrum of PFDMA and PFDMA-10T polyHIPE extracts. Reprinted 
from Whitely et al.146 
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After confirming an improvement in acute cytocompatibility with tetrathiol 
incorporation, hMSCs were seeded directly onto cleaned PFDMA control and 10 mol% 
thiol-methacrylate polyHIPEs up to one week to further characterize cell response. Thiol-
methacrylate polyHIPE scaffolds supported hMSC viability of greater than 80%, while 
PFDMA controls exhibited viability greater than 90% Figure 2.10. Minor differences in 
viability between scaffold compositions was attributed to differences in initial cell 
attachment as a result of altered surface chemistry and protein adsorption. In addition, a 2 
and 3 fold increase in cell number was observed at 11 days on PFDMA controls and thiol-
methacrylate polyHIPEs respectively, Figure 2.11. The ability of thiol-methacrylate 
polyHIPEs to support long-term proliferation permits further investigation into osteogenic 
activity of seeded hMSCs. Notably, the specimens were sterilized with ethanol washes 
prior to cell seeding that may remove extractables and not fully replicate the injected form, 
which is a limitation of the current study. In future studies, each of the components will 
be sterilized prior to HIPE formation and sterility maintained prior to injection. This 
method will permit cytocompatibility and other biocompatibility assessments immediately 
following injection and cure without additional processing. It is expected that possible 
leachables will likely to be removed by the native vasculature, as postulated previously 
for other fumarate systems.161 
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Figure 2.10. hMSC viability on PFDMA and PFDMA-10T polyHIPEs at 1, 3, and 7 
days (A). Micrographs illustrating live (green) and dead (red) cells on the respective 
polyHIPE sections at 7 days (B). Reprinted from Whitely et al.146 
 
 
 
 
 
Figure 2.11. Proliferation of hMSCs seeded on PFDMA and PFDMA-10T polyHIPEs at 
1, 6, and 11 days as determined by DNA quantification. hMSCs were cultured in growth 
media (GM) and osteogenic media (OM) with an initial cell seeding density was 50,000 
cells/cm2. Reprinted from Whitely et al.146 
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The ability to direct bone-marrow derived cells down a discrete lineage is a potent tool 
for improving the regenerative capacity of our tissue engineered graft. We previously 
demonstrated the ability of polyHIPE scaffolds to serve as a delivery vehicle for a 
multitude of osteoinductive agents and support osteogenic activity of seeded hMSCs as 
confirmed by early and late stage gene expression.129 Furthermore, unmodified PFDMA 
scaffolds also reported osteogenic differentiation under standard culture conditions 
demonstrating an inherent osteoinductive character of these grafts. In this study, ALP 
enzyme activity was assessed as an early marker of osteoblastic differentiation of seeded 
hMSCs to confirm that thiol-methacrylate polyHIPEs retained this ability to support 
osteogenic activity. ALP activity increased (2-3 fold) for all scaffold compositions at 11 
days for scaffolds cultured in both growth and osteogenic media, Figure 2.12. It was noted 
that the rate of proliferation decreased while the rate of increase in ALP activity increased 
for both scaffold compositions from day 6 to day 11, when hMSCs were cultured in 
ostegenic media. No significant differences were observed between PFDMA control and 
thiol-methacrylate polyHIPEs. These observations support established activity profiles for 
MSC differentiation and illustrate the retained ability of these grafts to support osteogenic 
activity. 
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Figure 2.12. Alkaline phosphatase activity of hMSCs seeded on PFDMA and PFDMA-
10T polyHIPEs at 1, 6, and 11 days. PolyHIPEs were cultured in growth media (GM) 
(A) and osteogenic media (OM) (B). Reprinted from Whitely et al.146 
 
 
 
Although initial activity of MSCs seeded on our polyHIPE graft provide a clear 
promise for success in vitro, a future goal of this project is the development of an injectable 
polyHIPE system with the potential to support encapsulation and in vivo delivery of these 
cells to the injury site. The addition of tetrathiol into our injectable polyHIPE may provide 
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added benefit in this work to adapt our system as a rigid cell carrier. Roberts et al. 
demonstrated that thiol-ene based polymerization mechanisms can have long-term effects 
on the quality of engineered cartilage in thiol-ene systems over acrylate based PEG 
hydrogel scaffolds.181 Furthermore, the role of thiol-ene chemistries in reducing 
intracellular ROS damage was noted, a characteristic of thiol-methacrylate polyHIPEs that 
would further support viability and retention of encapsulated cells.  
2.3.8. PolyHIPE Surface Modification 
In this work, methacrylated gelatin was utilized to modify polyHIPE pore surfaces 
fabricated with the macromer 1,4 butanediol dimethacrylate. The collagen denaturation 
process utilized to form gelatin exposes RGD binding sites that are strong promoters of 
cell attachment.182 Increased intensity of Picrosirius Red staining confirmed gelatin 
modification of polyHIPE pore surfaces post sectioning and sterilization procedures, 
Figure 2.13. It is hypothesized that the hydrophobicity of gelatin relative to macromer 
resulted in relocation of the protein closest to the aqueous phase at the pore wall. A 
corollary increase in attachment, viability, and spreading of hMSCs was observed on 
gelatin modified constructs as compared to untreated polyHIPEs. Viability on modified 
scaffolds was greater than 90% with a 50% increase in cell attachment. A significant 
increase in cell spreading was also observed. This work holds significant promise for 
future polyHIPE surface modification work as this approach can be utilized to incorporate 
targeted proteins capable of guiding cell activity. Specifically, a class of engineered, 
streptococcal collagen-like proteins are currently being explored due to their ability to 
present specific and targeted receptor binding motifs.183 Integrin mediated signaling plays 
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a prominent role in the regulation of hMSC differentiation and promotion of 
mineralization through both biomechanical and biochemical pathways.184, 185  The ability 
to not only control cell attachment but facilitate activation of targeted signaling pathways 
has the potential to significantly improve osteogenesis.  
 
 
 
 
Figure 2.13. The effect of gelatin surface modification on collagen staining (A), 
attached hMSC viability (B), hMSC adhesion (C), and hMSC morphology and spreading 
(D) of polyHIPE scaffolds. 
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2.3.9. Pilot Assessment of PolyHIPE Biocompatibility 
Pilot studies were performed to demonstrate the ability to deploy injectable HIPEs in 
vivo and characterize biocompatibility. PolyHIPE scaffolds injected into a critical sized 
rat calvarial defect were evaluated for host response at 4 weeks and compared to an empty 
defect control, Figure 2.14. PolyHIPE grafts supported cell attachment and migration 
demonstrated by moderate lymphocytic/plasmacytic infiltrate. Ordinal scoring of negative 
control and polyHIPE (n=6 evaluated tissue sections) indicated no significant differences 
in the biologic response, with the exception of lymphocyte infiltrate. A rat femoral defect 
model was utilized to characterize polyHIPE integration with native tissue prior to 
investigation in load bearing models, Figure 2.15. Scanning electon microscopy of filled 
defects demonstrates excellent, microscale integration with the native bone tissue. Success 
of this procedure allows for more in depth investigation of scaffold integration through 
mechanical, push out testing. Overall, these studies represent an important milestone in 
the development of an injectable bone graft.  
 
 
 
 63 
 
 
Figure 2.14. Biocompatibility of polyHIPE in rat calvarial defect model. A: Negative 
control defects contain neovascularization (arrowheads), spindle shaped fibroblasts, and 
collagenous matrix. B: The polyHIPE treated defect contains similar fibrous tissue 
(arrowheads). C: Ordinal scoring of negative control and polyHIPE (n = 6 tissue 
sections) indicated no significant differences in the biologic response, except for 
lymphocyte infiltrate, which was increased in polyHIPEs. 
 
 
 
 
 
Figure 2.15. Rabbit medial femoral condyle defect with diameter 3.5 mm and depth 
of 5 mm (white arrow) (A). PolyHIPE injected into the defect (B). PolyHIPE 
interdigitates with the bone, and solidifies (black arrow) (C). Harvested and sectioned 
image of the filled defect (D), and representative SEM images of the injected polyHIPE 
(E) and bone/graft interface (F). 
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2.4. Conclusions 
This study demonstrates the potential of thiol-methacrylate polyHIPEs to serve as an 
injectable bone graft with improved resistance to oxygen inhibition. Incorporation of 
tetrathiol monomer provided more rapid and complete network formation in the presence 
of oxygen with minimal impact on compressive modulus, yield strength, and pore 
architecture. The introduction of β-thioesters also served to increase the rate of hydrolytic 
degradation of the polyHIPE, providing a potent tool for tuning desired degradation 
profiles. Finally, thiol-methacrylate polyHIPEs demonstrated strong potential as a tissue 
engineered scaffold by supporting extended viability and proliferation of hMSCs and 
retaining the osteoconductive character previously observed in our PFDMA system. 
Overall, the investigation of thiol-methacrylate based grafts improves the translational 
potential of polyHIPEs by providing a material with improved function in clinically 
relevant environments and demonstrating the potential to influence cellular activity.  
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CHAPTER III  
IMPROVED IN SITU SEEDING OF 3D PRINTED BONE GRAFTS USING CELL-
RELEASING HYDROGELS 
 
3.1. Introduction 
Despite the high regenerative potential of bone, treatment of large defects and 
nonunions remains a significant challenge and often requires surgical intervention. 
Autologous grafting serves as the current standard of care due to its high regenerative 
capacity. However, this treatment is unavailable in a large number of patients due to 
anatomical limitations associated with harvesting.186 Patients eligible for autologous 
grafting face elevated risk of donor site morbidity, pain, and infection. Tissue engineering 
aims to provide a bone replacement that combines the regenerative potential of autologous 
grafts with the availability and tunability of synthetic materials. Tissue engineered bone 
grafts are designed to be a porous scaffold that matches defect geometry, degrades at a 
rate complementary to new tissue formation, and exhibits requisite mechanical properties 
to withstand physiological loading.187, 188 It is often challenging to achieve this 
combination of properties using traditional fabrication techniques. For example, highly 
porous constructs that facilitate nutrient and waste transport often struggle achieving 
desired mechanical properties.171, 172 Expansion of 3D printing technologies into tissue 
engineering has provided researchers new tools to independently control and optimize 
these properties. We recently developed a multi-modal printing system to generate tissue 
engineered scaffolds that mimics the native structure of bone.189, 190 In this system, 
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fumarate-based emulsion inks with hierarchical porosity were reinforced with a poly(ε-
caprolactone) or poly(lactic acid) shell to achieve simultaneous improvements in 
permeability and compressive properties. 
In addition to the design of scaffold properties, success as a tissue engineered bone 
graft depends on the delivery or recruitment of mesenchymal stem cells (MSC). These 
multipotent progenitor cells aid regeneration through a variety of mechanisms including 
serving as new centers of bone formation and secretion of trophic factors that modulate 
inflammation, stimulate angiogenesis, and limit fibrosis.65, 191-193 Despite the therapeutic 
advantages of MSCs, traditional cell delivery (e.g. direct injection of stem cells via syringe 
or catheter) are associated with limited cell engraftment, often retaining less than 5% of 
injected cells.81, 82, 194 Furthermore, the hostile environment of injured or diseased tissue 
can reduce retention of transplanted cells by depriving them of nutrients or subjecting 
them to early clearance by surveying inflammatory cells.  
To overcome this limitation, researchers have investigated and reviewed numerous 
hydrogel carriers to improve retention and viability of transplanted cells.83, 84, 195, 196 
Encapsulation within an external matrix improves retention by acting as a mechanical 
barrier to cell wash out and providing an improved substrate for tissue engraftment. 
Multiple natural and synthetic hydrogel platforms have been investigated for cell 
encapsulation based on modfied gelatin, fibrin, and poly(ethylene glycol)-based 
systems.197-202 Although these have improved cell retention, use of hydrogel scaffolds 
alone are not ideal for bone grafting due to their poor compressive properties. Multiple 
groups have reported on the benefits of using mechanically robust scaffolds coupled with 
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microsphere mediated cell delivery to improve both cell retention and mechanical 
stability. Alginate based microspheres have been utilized as cell delivery vehicles in both 
calcium phosphate and polyurethane scaffolds.93, 94 Although these systems illustrate the 
potential of combination delivery methods, these protocols often require significant 
processing prior to use that add significant cost and regulatory hurdles. In contrast, we 
propose to use an in situ curing hydrogel as a cell carrier to seed the bone graft with MSCs 
at the time of surgery, Figure 3.1. Combination with advanced 3D manufacturing 
technologies has the potential to generate a graft with patient specific geometries and 
improved retention of stem cells. 
 
 
 
 
Figure 3.1 Schematic illustrating hMSCs loading in hydrogel precursor solutions (A), 
injection and encapsulation in 3D printed polyHIPE scaffold (B), and protection during 
early stages of implantation (C). 
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In this study, 3D printed polyHIPE scaffolds were seeded with MSCs using a cell-
releasing hydrogel carrier that cures in situ using redox initiation. The hydrolytically 
degradable macromer, poly(ethylene glycol)-dithiothreitol, was investigated as a cell 
carrier and the effect of the oxidant-to-reductant ratio on network formation time, sol-gel 
fraction, and swelling ratio was investigated to identify candidate cell carriers. The 
viability and release profiles of MSCs encapsulated in these in situ cured hydrogels was 
then characterized. To confirm the benefits of hydrogel delivery in 3D printed polyHIPEs, 
MSC-loaded macromer solutions were injected into multi-layered constructs and cell 
distribution compared to a traditional suspension seeding method. Mesenchymal stem cell 
activity on 3D printed polyHIPEs was monitored using established alkaline phosphatase 
(ALP) and mineralization assays to ensure delivered cells retained the ability to undergo 
osteoblastic differentiation. We previously reported that unmodified scaffolds based on 
propylene fumarate dimethacrylate (PFDMA) promoted osteoblastic differentiation under 
standard culture conditions, demonstrating the inherent osteoinductive character of these 
grafts.129 In the current study, we aimed better understand the mechanism behind this 
osteoinductive character by isolating the effects of scaffold chemistry and surface area on 
osteoblastic differentiation. Collectively, this work aims to highlight the potential of cell-
laden 3D printed scaffolds to serve as rigid cell carriers and improve the regenerative 
capacity of tissue engineered bone grafts. 
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3.2. Materials and Methods 
3.2.1. Materials 
Polyglycerol polyricinoleate (PGPR 4125) was donated by Palsgaard. Human 
mesenchymal stem cells were provided by the Texas A&M Health Science Center College 
of Medicine Institute for Regenerative Medicine at Scott & White. All other chemicals 
were purchased and used as received from Sigma–Aldrich, unless otherwise noted.  
3.2.2. hMSC Culture 
Bone marrow-derived hMSCs were obtained as passage 1 from the Center for the 
Preparation and Distribution of Adult Stem Cells at Texas A&M Health Science Center 
College of Medicine, Institute for Regenerative Medicine at Scott & White through NIH 
Grant # P40RR017447. Cells were cultured to 80% confluency on tissue-culture 
polystyrene flasks in standard growth media containing Minimum Essential Media α 
(MEM α, Life Technologies) supplemented with 16.5% fetal bovine serum (FBS, Atlanta 
Biologicals) and 1% L-glutamine (Life Technologies) prior to passaging. All experiments 
were performed with cells at passage 3. 
3.2.3. PEGDTT Synthesis 
Poly(ethylene glycol)-dithiothreitol (PEGDTT) was synthesized by adding a solution 
of d,l-dithiothreitol (DTT), TEA, and DCM dropwise to a solution of PEGDA 2kDa in 
DCM. The molar ratios of DTT, PEGDA and TEA were 2:3:0.9. After the addition of the 
DTT and TEA solution in DCM, the reaction was stirred for 24 hours at room temperature. 
The resulting solution was then precipitated in cold diethyl ether, washed, filtered, and 
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dried under ambient conditions for 24 hours. The resulting macromer was placed under 
vacuum to remove excess solvent until the weight was stabilized. 
3.2.4. Fabrication of Redox Initiated hMSC-releasing Hydrogels  
Hydrogel solutions were prepared by dissolving PEGDTT (10 wt%) in PBS containing 
either ammonium persulfate as oxidant or iron gluconate as reductant. Precursor solutions 
were then loaded into a double barrel syringe and injected through a mixing head to 
facilitate crosslinking. In specified studies, precursor solutions were used to resuspend 
hMSCs at a density of 1 million cells/mL prior to loading. Cell-laden hydrogels were 
injected either into neat hydrogel constructs (5 mm diameter x 1 mm height) or used to fill 
pre-fabricated polyHIPE prints and allowed to cure for 5 minutes. After the specified time, 
cell-laden constructs were moved to culture media and incubated. 
3.2.5. Rheological Characterization 
Work and set times of the polyHIPEs were characterized using an Anton Paar MCR 
301 rheometer following adapted procedures. Storage, loss, and complex moduli were 
measured every 3 s using a parallel-plate configuration with a 1 mm gap and 0.5% strain. 
Redox initiated hydrogels were injected through a mixing head onto the plate heated to 37 
°C. Gelation onset was determined as the crossing of loss and storage modulus. Complete 
network formation was determined as the fourth point after which there was a less than 
1% change in complex viscosity. Values were reported as the average of three specimens. 
3.2.6. Characterization of Network Formation 
To characterize sol-gel fraction of redox initiated hydrogels, precursor solutions were 
injected into cylindrical tubes and allowed to cure for 1h. Specimens were then sectioned 
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(8 mm diameter, 2 mm thick) and vacuum-dried for 24 h. Dry polymer mass was obtained 
and placed in dichloromethane (DCM) at a ratio of 1 mL of DCM to 10 mg of specimen 
to facilitate dissolution of un-cross-linked macromer. After extraction for 24 h, the DCM 
was decanted and the specimens vacuum-dried for 24 h at ambient temperature. The gel 
fraction was calculated as the final weight divided by original weight. Similarly, swelling 
ratio was determined from bulk cured samples. Specimens were swelled in RO water to 
reach equilibrium swelling mass (Ws). Then, specimens were dried under vacuum for 24 
hours and weighed to assess dry (polymer) mass (Wd). The equilibrium volumetric 
swelling ratio, Q, was calculated from the equilibrium mass swelling ratio: Ws/Wd. 
3.2.7. Preparation of Emulsion Inks and 3D Printed PolyHIPEs 
Propylene fumarate dimethacrylate (PFDMA) was synthesized in a two-step process 
detailed previously. Briefly, propylene oxide was added dropwise to a solution of fumaric 
acid and pyridine in 2-butanone and refluxed at 75°C to yield the diester, bis(1,2 
hydroxypropyl). Following purification, the diester was end-capped with methacrylate 
groups using methacryloyl chloride in the presence of trimethylamine and purified to yield 
the final product. To prepare emulsion inks, propylene fumarate dimethacrylate (PFDMA) 
was combined with 10 wt% surfactant (polyglycerol polyricinoleate), 1 wt% initiator 
(phenylbis (2,4, 6-trimethylbenzoyl)- phosphine oxide)(BAPO), and mixed in a FlacTek 
Speedmixer. An aqueous solution of calcium chloride (1 wt%) was then added to the 
organic phase (w:o 75:25) and mixed. Emulsion inks were extruded layer-by-layer through 
respective syringes and motor actuated plungers. The emulsions inks rapidly cured after 
deposition by UV exposure. 
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3.2.8. hMSC Viability during Preparation, Encapsulation and Degradation 
Investigation of hMSC viability and morphology was performed to ensure redox 
initiated PEGDTT hydrogels were cytocompatible during precursor preparation, 
encapsulation and carrier degradation stages. Viability was assessed utilizing the 
LIVE/DEAD assay kit (Molecular Probes) after specified exposure conditions. Briefly, 
cells were washed with PBS, stained with 2 µM calcein-AM (live) and 2 µM ethidium 
homodimer-1 (dead) for 30 minutes at 37°C, and washed with PBS for imaging. Imaging 
(3 images per specimen) was conducted on four specimens (n = 12) with a fluorescence 
microscope (Nikon Eclipse TE2000-S).  
3.2.9. Distribution of hMSCs in 3D Printed PolyHIPE Scaffolds  
A Quant-iT™ PicoGreen® dsDNA Assay Kit (Molecular Probes) was utilized to 
quantify cell distribution throughout multi-layer polyHIPE scaffolds. hMSC-PEGDTT 
precursor solutions were prepared and injected 3mm tall polyHIPE prints, allowed to cure 
for 5 minutes, and placed in standard growth media. Cell density was characterized at 1 
and 7 days post release at depths of  1, 2, and 3mm to confirm improved distribution of 
hMSCs throughout the bulk of the scaffold. At selected time points, polyHIPEs were 
removed from the culture wells and placed in unused wells for thermal shock lysis 
procedure to ensure only DNA from cells adhered to the scaffolds was measured. The 
assay was performed according to manufacturer instructions and fluorescence intensity 
was assessed using a plate reader (Tecan Infinite M200Pro) with excitation/emission 
wavelengths of 480/520 nm, respectively. Average cell number was determined by 
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converting dsDNA values to individual cell number using 6.9 pg DNA/cell. Specimens 
were analyzed in triplicate. 
3.2.10. Alkaline Phosphatase Activity of hMSCs Released into 3D Printed PolyHIPE 
Scaffolds 
Alkaline phosphatase activity of cells encapsulated and released into 3D printed 
polyHIPE scaffolds was determined by monitoring the conversion of p-nitrophenyl 
phosphate (PNPP, Thermo Scientific) to p-nitrophenol. After 24 hours post encapsulation, 
growth media or osteogenic media (growth media supplemented with 50 μg/mL ascorbic 
acid, 10 mM β-glycerophosphate, and 10 nM dexamethasone) was added and changed 
every 2 days for 21 additional days following measurement of ALP activity. Scaffold 
cultures were lysed using thermal shock treatment and incubated with pNPP for 30 min. 
ALP activity was determined as the rate of PNPP conversion to p-nitrophenyl by 
measuring the absorbance at 405 nm (Tecan Infinite M200Pro) and normalized to cell 
number obtained from the PicoGreen assay. Specimens were analyzed in triplicate. 
3.2.11. Mineralization Activity of hMSCs Released into 3D Printed PolyHIPE Scaffolds 
Alizarin red staining was performed to detect calcium phosphate mineral deposition 
of hMSCs encapsulated and released into 3D printed polyHIPE scaffolds. After 24 hours 
post encapsulation, growth media or osteogenic media (growth media supplemented with 
50 μg/mL ascorbic acid, 10 mM β-glycerophosphate, and 10 nM dexamethasone) was 
added and changed every 2 days for 28 additional days following staining of mineralized 
nodules. hMSCs were fixed in 3.7% glutaraldehyde and incubated for 5 minutes in 2% 
Alizarin Red S. Scaffolds were then washed with PBS to remove excess stain and 
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photographed under optical microscopy. A semi-quantitate procedure was then performed 
by destaining scaffolds in 10% acetic acid solution and monitoring absorbance at 405 nm. 
Specimens were analyzed in triplicate. 
3.2.12. Mechanism of PolyHIPE Osteoinductivity 
To investigate the underlying mechanism of polyHIPE osteoinductivity, ALP activity 
of seeded hMSCs was monitored on three differing substrates, PFDMA polyHIPEs, 
PFDMA films, and poly(lactic acid) (PLA) films. Briefly, poly(lactic acid) filament was 
heated to 200°C, extruded into films, and allowed to cool under ambient temperatures. 
PFDMA films were fabricated by mixing the pre-polymer with 1 wt% BAPO, adding 
dropwise into round molds and UV cured.  Finally, PFDMA polyHIPE scaffolds were 
fabricated as described previously with the exception of utilizing a 100% infill density. 
Scaffolds were sterilized using ethylene oxide sterilization prior to cell culture. 
3.2.13. Statistical Analysis  
The data are displayed as mean ± standard deviation for each composition. An analysis 
of variance (ANOVA) comparison was used for multiple composition comparisons with 
a Tukey’s multiple comparison to analyze the significance of the data. A Student’s t-test 
was performed to determine any statistically significant differences if only two 
compositions were present. All tests were carried out at a 95% confidence interval 
(p<0.05). 
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3.3. Results and Discussion 
3.3.1. Rheological Characterization of Redox Initiated PEGDTT Hydrogels 
Photopolymerization of acrylated poly(ethylene glycol) is a widely studied delivery 
platform that allows cell encapsulation in mild conditions with high cell survival.88, 203, 204  
Despite these advantages, reliance on an external UV source to initiate polymerization 
often results in depth dependent properties that can limit translation of these systems.153 
Increased depths and irregular geometries of bone injuries make sufficient filling and 
curing within these defects difficult with photopolymerization alone. In contrast, this study 
aimed to develop and characterize an in situ curing hydrogel based on redox initiation of 
the biodegradable macromer, poly(ethylene glycol)-dithiothreitol. An in situ curing cell 
carrier would allow for facile incorporation of marrow derived cells in the surgical setting 
and improve spatial distribution of cells within a tissue engineered scaffold. To assess the 
feasibility of the proposed carrier, polymerization times were characterized as a function 
of initiator concentration to ensure encapsulation occurred in a relevant time scale. 132  
First, onset of gelation was determined by monitoring the rheological transition between 
the liquid and gelled state to ensure appropriate time for injection and filling of the scaffold 
was allowed, Figure 3.2A. Next, complete network formation was determined by 
identifying the plateau of complex viscosity to ensure uniform property formation and 
retention of cells at the defect site, Figure 3.2B. Multiple researchers have reported use of 
the water-soluble initiator, ammonium persulfate (APS) in cell encapsulation platforms.90, 
205 Temeneoff et al. demonstrated rapid encapsulation of rat marrow stromal cells in a 
thermal initiated, oligo(poly(ethylene glycol) fumarate) hydrogel with gelation onset 
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occurring in less than 5 minutes at an initiator concentration of 25 mM. Traditional redox 
carriers such as these often utilize N, N, N, N-tetramethylethylendiamine (TMED) to 
accelerate radical formation. As an alternative, ferrous based reducing agents facilitate 
radical formation at an elevated rate, introducing the potential to retain rapid 
polymerization rates with reduced initiator concentrations.206, 207 In this study, ammonium 
persulfate was added at concentrations of 1.25, 2.5, 5, 10 and 25 mM with equal molar 
iron gluconate dihydrate added as reducing agent. As expected, increasing initiator 
concentration resulted in more rapid gelation onset ranging from approximately 10 
minutes to less than 10 seconds. Uniquely, the use of a ferrous reducing agent allowed for 
gelation to occur at rates comparable to other APS systems with the benefit of a 10-fold 
reduction in required concentration. Furthermore, complete network formation time was 
could be tuned from approximately 15 minutes to less than 5 minutes. To further develop 
tools that could be utilized to modulate cure rate independent of initiator concentration, 
the effect of initator:reductant ratio on cure rate was explored by adding iron gluconate 
dihydrate concentration at relative molar concentrations of 1:0.5, 1:1, 1:2 (ammonium 
persulfate:iron gluconate dihydrate). Thoughtful selection of iron based reducing agent 
concentration is required as excessive concentrations of ferrous ions are known to inhibit 
polymerization through oxidation of propagating radicals. In this work, no inhibitory 
effects of increasing iron gluconate concentration was observed and it is hypothesized that 
a more rapid production of the APS-iron gluconate complex led to a tunable range of cure 
rates with a single initiator concentration. A minimum of 2-fold range in polymerization 
times were observed with increasing ratio of reductant to initiator. Studies investigating 
 77 
 
enzyme-mediated reodox initiation of hydrogel cell carriers have also demonstrated no 
inhibitory effects in similar ranges of ferrous ion concentration.208 However, the potential 
impact on final double bond conversion has been noted, and as such, it is critical to ensure 
requisite network formation in this system. 
 
 
 
 
Figure 3.2. Effect of initiator concentration and reducing agent ratio on gelation onset 
(A) and complete network formation (B) of hydrogel carrier. The + represents a gelation 
and network formation time of greater than 30 minutes. The * represents a gelation onset 
time of less than 10 seconds. All data represents average ± standard deviation for n = 3. 
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3.3.2. Network Formation of Redox Initiated PEGDTT Hydrogels 
Complete and consistent network formation is critical to controlling carrier properties 
and degradation profiles.209, 210 To this end, sol-gel fraction and swelling ratio were 
characterized to assess the effect of oxidant and reductant concentration on hydrogel 
network formation, Table 3.1 Sol-gel fraction increased with elevated initiator, ranging 
from greater than ~95% for 25 mM concentrations, to ~70% for 1.25 mM concentrations. 
For comparison, photopolymerized PEGDTT hydrogels were cured with 5mM 
concentration of irgacure 2959 and exhibited a sol-gel fraction of 98%. Differences in sol-
gel fraction for redox systems versus UV systems is attributed to dissociation of the 
photoinitiatior resulting in a pair of free radicals, versus only a single free radical site being 
generated with the formation of each redox complex site.207 Furthermore, due to double 
barrel mixing, initiator concentration is diluted in half upon mixing of the two phases. 
Therefore, when matched by radical generation, sol-gel fractions were more closely 
aligned at greater than 95%. Hydrogel swelling ratios further confirmed efficient network 
formation with a less than 15% change in swelling for all compositions when compared 
to photoinitiated control. After completing physical characterization of the hydrogel 
carrier, selection criteria were implemented to identify potential carriers to investigate in 
cytocompatibility studies. Initiator concentrations of 2.5 mM or greater had complete 
network formation times of less than 10 minutes, sol-gel fraction greater than 80%, and 
less than 10% change swelling. As such, these compositions moved forward in the testing. 
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Table 3.1. Effect of initiator and reducing agent concentration on hydrogel compressive 
modulus, swelling rato, and gel fraction. 
 
[APS] APS:IG 
(molar ratio) 
Gel 
Fraction 
Swelling 
Ratio 
1.25 mM 
1:0.5 -- -- 
1:1 -- -- 
1:2 66 ± 6 18.2 ± 2 
2.5 mM 
1:0.5 -- -- 
1:1 78 ± 4 18.9 ± 4 
1:2 81 ± 6 17.6 ± 6 
5 mM 
1:0.5 81 ± 2 18.4 ± 2 
1:1 88 ± 2 17.2 ± 3 
1:2 90 ± 2 17.2 ± 4 
10 mM 
1:0.5 85 ± 2 17.1 ± 3 
1:1 88 ± 7 17.1 ± 1 
1:2 88 ± 4 17.5 ± 1 
25 mM 
1:0.5 91 ± 2 16.9 ± 3 
1:1 95 ± 2 16.8 ± 3 
1:2 95 ± 2 16.8 ± 2 
Irgacure 2959 
5 mM -- 98 ± 1 16.4 ± 1 
 
 
 
3.3.3. Effect of Redox Initiation on Stem Cell-Loaded Hydrogel Viability 
In situ delivery of marrow derived cells within a biodegradable carrier has the potential 
to improve translation by eliminating timely pre-culture and reducing external equipment 
required for the surgical procedure. However, these benefits must be achieved without 
compromising cytocompatibility observed in photoinitiated systems.211, 212 As PEGDTT 
has been demonstrated cytocompatible in previous cell encapsulation studies, the only 
anticipated source of potential cytotoxicity was due to the redox initators.91, 213 Cell 
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delivery in this in situ system occurs through mixing of two distinct hydrogel suspensions 
containing the cell payload and either the initiator or reducing agent. As a result, it was 
critical to identify the exposure limits of these agents to ensure a formulation was selected 
that optimizes cell survival during encapsulation. Previously, it has been reported that 
extended exposure to elevated concentrations of redox initiators can result in poor 
cytocompatibility resulting from significant changes to pH.214 However, cell carrier 
studies that utilize redox initiator concentrations at the maximum end of our experimental 
design demonstrate minimal pH change in buffered environments, with a return to neutral 
conditions after mixing.90, 198 These studies also confirmed cells encapsulated in redox 
carriers supported markers of osteoblast and chondrocyte differentiation. hMSC viability 
was first assessed following ten minute exposure to initiator or reducing agent, mimicking 
anticipated conditions during early stages of carrier polymerization. As shown in Figure 
3.3A, all concentrations of APS and iron gluconate supported viability greater than 95%. 
Next, to ensure encapsulated cells did not experience long term effect due to precursor 
exposure, cells were cultured for an additional 24h at a 10-fold dilution to mimic hydrogel 
swelling and dilution of excess initiator following cure, Figure 3.3B. All APS 
concentrations lower than 25 mM supported high viability of greater than 95%. The slight 
reduction in viability, ~70%, for the 25 mM APS is attributed to the reduction in media 
pH resulting from initiator addition. After confirming hMSCs would survive exposure to 
initiating agents, the effect of initiator mixing, radical formation, and resultant 
encapsulation on viability was assessed, Figure 3.3C. Two critical observations were 
made during the encapsulation procedure. First, as was seen in single the initiator studies, 
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all compositions below 25 mM experienced excellent viability and retained high cell 
densities. Second, a cell-dependent effect was observed on the lowest, 2.5 mM 
concentration, resulting in a slower cure rate than was observed during rheological 
characterization. The radical scavenging effect of cell encapsulation is believed to have 
caused this composition to cure slower than desired for an in situ encapsulation procedure. 
As a result, the 10 mM formulation was selected for subsequent cell release and osteogenic 
activity studies. 
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Figure 3.3. Percent hMSC viability following 10 min exposure to redox agents, 
ammonium persulfate and iron gluconate (A); 24h additional culture (B). Percent hMSC 
viability and cell density following carrier encapsulation with micrographs illustrating 
live (green) and dead (red) cells in respective hydrogel formulations (C). All data 
represents average ± standard deviation for n = 12. The * and ° represent significant 
difference (p<0.05) for 25 mM concentration compared to other concentrations. 
 
 
 
3.3.4. Improved Stem Cell Loading of 3D Printed PolyHIPE Scaffolds 
The primary aim of this work was to develop a transient, hydrogel carrier that could 
improve cell retention during early stages of delivery, then undergo biodegradation and 
provide targeted stem cell release into 3D printed polyHIPE scaffolds under more 
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hospitable conditions. Degradable hydrogels formed by the Michael-type addition 
reaction of dithiothreitol and poly(ethylene glycol) diacrylate have been successfully 
explored for cell encapsulation and delivery applications.91, 213, 215 Biodegradation is 
achieved by introducing hydrolytically labile DTT linkages into the macromer backbone. 
Resultant thioether linkages change the atomic charge of adjacent acrylate ester bonds, 
increasing susceptibility to nucleophilic attack and hydrolytic degradation.216 Simulated 
degradation profiles for the selected hydrogel composition demonstrated complete 
hydrolytic degradation after 7 days in buffered saline conditions. Cell-loaded PEGDTT 
hydrogels were cultured for 2 weeks to assess hMSC loaded carrier degradation and 
viability of released cells. As high encapsulation viability was observed in PEG based 
systems under this target degradation time frame, any viability effects would arise from 
exposure to carrier degradation products.87 Partial release of the hMSC loaded carrier was 
observed after 4 days in culture, with significant cell numbers remaining entrapped in the 
hydrogel network (data not shown). After 7 days, hMSCs were completely released from 
the hydrogel carrier and successfully adhered to tissue culture polystyrene substrate and 
polyHIPE substrates, Figure 3.4A. Viability was monitored for an additional 7 days to 
ensure cells remained viable and persisted on the target substrate, Figure 3.4B. hMSCs 
released onto 3D printed polyHIPE scaffolds demonstrated viability of greater than 90% 
with morphology matching that of a direct-seeded polyHIPE scaffold, indicating no effects 
of degradation products on cell survival.189 In this study, a single hydrogel degradation 
profile was studied; however, use of the PEGDTT platform allows for facile tuning of 
degradation through modulation of the number of DTT linkages.213 Modulation of carrier 
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degradation profile has been shown to play a major role in cell retention. Qui et al. 
demonstrated that a range of carrier degradation profiles could be engineered utilizing the 
PEGDTT macromer and that increasing carrier degradation rate resulted in a greater than 
2-fold increase in cell retention in a tendon tissue explant model.91  
 
 
 
 
Figure 3.4. Micrographs illustrating live (green) and dead (red) cells 1 day post 
encapsulation and 7 days post release onto TCPS and polyHIPE substrates (A). Percent 
hMSC viability 1 day and 7 days following release and attachment onto TCPS and 
polyHIPE substrates (B). All data represents average ± standard deviation for n = 12. 
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A major hurdle to achieving the full potential of stem cell therapies is retaining cells 
at the target site after transplantation. Direct injection often results in rapid dispersal of 
cells away from the injury site, resulting in subtherapeutic retention levels.81, 217 Rapid 
curing hydrogels act as a physical barrier to cell dispersal and 3D substrate to improve cell 
engraftment. A primary hypothesis of this work was that an in situ curing hydrogel carrier 
would improve spatial distribution and retention of hMSCs in our 3D printed polyHIPE 
grafts. To this end, cell density was monitored after encapsulation and release onto 
multilayered polyHIPE scaffolds and compared to a standard suspension seeding method, 
Figure 3.5. Cell distribution was quantified at 1 mm depths with a total construct size of 
3 mm. In contrast to standard suspension seeding, encapsulation loading resulted in 
uniform cell distribution across the three scaffold layers. Suspension seeding 
demonstrated irregular distribution with a significantly reduced number of cells observed 
on the top two layers and high settling at the bottom most layer. Furthermore, a 3-fold 
increase in cell density was observed on the top two layers while retaining a 2-fold increase 
over the bottom layer. This improved control over seeding density across scaffold depth 
is a significant advantage over standard seeding techniques as seeding density has been 
shown to influence osteoblastic differentiation of transplanted marrow stromal cells on 
poly(propylene fumarate) scaffolds.218 Kim et al. investigated the role of cell-cell 
paracrine signaling distance, demonstrating that controlling cell seeding density resulted 
in elevated osteoblastic gene expression of marrow derived cells. It is believed that in vivo 
application of this system will result in greater improvements in cell retention as rapid 
wash out effects are often observed during the early stages following surgery.219 Current 
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studies are investigating improved loading of printed constructs with sizes greater than 2 
cm in the aim of developing a platform to explore healing in critical sized defects of more 
clinically relevant large animal models.79, 220, 221 
 
 
 
 
Figure 3.5. Distribution of hMSCs using carrier seeding onto multilayer polyHIPE 
scaffolds determined by dsDNA quantification and compared to suspension seeding 
control (A). Representative micrographs of top, middle and bottom layers of scaffold 
(B). All data represents average ± standard deviation for n = 3. The * represents 
significant difference (p<0.05) between suspension and carrier seeding at specified layer. 
 
 
 
3.3.5. Osteoblastic Activity of hMSCs Released into 3D Printed PolyHIPE Scaffolds 
To fully assess the potential of this in situ cell carrier to improve the regenerative 
capacity of our 3D printed bone graft, it was essential to confirm encapsulated stem cells 
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retained their potency and ability to undergo osteoblastic differentiation post release. To 
this end, alkaline phosphatase activity was investigated as an early marker of 
differentiation at 7 and 14 days post release onto tissue culture polystyrene and polyHIPE 
substrates, Figure 3.6. ALP activity of hMSCs released onto TCPS increased ~3-fold 
when cultured in osteogenic conditions compared to control cells cultured in standard 
growth conditions. A 7-fold increase in ALP activity was observed at 7D post release on 
polyHIPE substrates, with no statistical effect of culture in osteogenic media observed. 
This peak was followed by a 5-fold increase in activity at 14D for polyHIPE substrates in 
osteogenic conditions. These expression profiles support conclusion of osteoblastic 
differentiation as observed in other systems investigating MSC differentiation.222, 223 It is 
noted that encapsulated cells also retained proliferative potential as demonstrated by an 
increase in cell density during the two week period post release. Next, mineralization was 
characterized as a late stage marker of differentiation. Alizarin red staining indicated 
encapsulated hMSCs retained the ability to facilitate mineralization 4 weeks following 
release onto TCPS substrates, Figure 3.7A. Calcium deposition was further characterized 
as a function of TCPS or polyHIPE substrate, Figure 3.7B-C. A synergistic effect was 
observed for hMSCs cultured on polyHIPE scaffolds in osteogenic conditions as a 5-fold 
increase in calcium deposition was observed over hMSCs cultured on TCPS in same 
conditions. Overall, these profiles support retention of stem cell potency after 
encapsulation and promotion of osteoblastic activity after release onto 3D printed 
polyHIPEs, demonstrating the strong potential of stem cell seeded polyHIPE grafts.  
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Figure 3.6. Adhesion of hMSCs released onto TCPS and polyHIPE substrates 
determined by dsDNA quantification (A). Alkaline phosphatase activity of hMSCs 7D 
and 14D post carrier release. Cells were cultured in growth media (GM) and osteogenic 
media (OM) as positive control. All data represents average ± standard deviation for n = 
3. The * and ° represent significant difference (p<0.05) for TCPS substrates compared to 
polyHIPEs at indicated time points. The + represents significant difference (p<0.05) for 
ALP activity on polyHIPE substrates at 14D. 
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Figure 3.7. Alizarin red staining of hMSC cultures 4 weeks following carrier release. 
hMSC mineralization post release onto TCPS substrates in growth vs osteogenic media 
(A). Effect of release substrate (TCPS vs polyHIPE) and media conditions (growth vs 
osteogenic) on hMSC mineralization (B). Semi-quantitative analysis of mineralization 
determined by alizarin red stain recovery (C). All data represents average ± standard 
deviation for n = 4. The * represents significant difference (p<0.05) between all 
compositions. 
 
 
 
We previously demonstrated the ability of fumarate-based polyHIPEs to promote 
osteoblastic activity in the absence of dexamethasone supplements through increased 
deposition of media derived calcium ions onto the polyHIPE surface.129 In addition to 
confirming osteogenic potential, this study aimed to elucidate a potential mechanism 
behind this increased calcium deposition and assess its impact on osteoblastic 
differentiation. Extracellular calcium is known to play a key role in bone regeneration via 
direct activation of Ca-sensing receptors that result in increased osteoblast proliferation, 
expression of osteoinductive factors, and matrix mineralization.224-226 To this end, three 
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substrates were tested (PFDMA polyHIPE, PFDMA film and PLA film) to isolate and 
explore the effects of surface area and scaffold chemistry on calcium deposition, Figure 
3.8. Alizarin red staining was performed on neat, cell-free scaffolds that had been soaked 
in growth media for 2 weeks for a qualitative assessment of calcium deposition. Fumarate-
based chemistries have been shown to support surface mineralization when soaked in 
concentrated solutions of simulated body fluid.227 In this study, calcium concentrations 
were limited to those present in basal media, ~1.6 mM, plus calcium found in the fetal 
bovine serum supplement. Despite a buffered environment conducive to mineral 
deposition, minimal calcium was observed on neat PFDMA and PLA films.  In contrast, 
PFDMA polyHIPEs displayed significant levels of staining. Surface roughening has been 
used previously in titanium implants to provide an improved substrate for apatite 
precipitation.228, 229 Specifically, Chen et al. identified surface grooves approximately 3 
microns wide to be ideal for surface mineralization.228 It is hypothesized that the increased 
surface area of polyHIPE scaffolds over neat films, combined with a pore size on the scale 
of several microns had a similar effect, providing an ideal substrate for surface deposition. 
Initial investigation of hMSC activity supports this hypothesis as polyHIPE scaffolds 
promoted increased levels of ALP activity in standard growth media. Elevated activity 
was observed when cultured in osteogenic conditions as the substrate most likely provided 
an ideal surface for nucleation and mineral growth.  
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Figure 3.8. Effect of scaffold chemistry (PFDMA vs PLA films) and scaffold porosity 
(PFDMA polyHIPE vs PFDMA film) on calcium deposition in cell free conditions (A). 
Quantification of hMSC adhesion on varied substrate determined by dsDNA 
quantification (B). Effect of substrate on hMSC alkaline phosphatase activity after 14 
days (C). Cells were cultured in growth media (GM) and osteogenic media (OM) as 
positive control. All data represents average ± standard deviation for n = 4. The * 
represents significant difference (p<0.05) for indicated composition compared to all 
others in respective media. 
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3.4. Conclusions 
This study demonstrates the ability of biodegradable poly(ethylene glycol)-
dithiothreitol hydrogels to serve as injectable stem cell carriers and improve in situ seeding 
of 3D printed polyHIPE grafts. Oxidant and reductant concentration were modulated to 
achieve desired cure rates while maintaining high cell viability during cure and after 
release. This redox-based initator system demonstrated the ability to encapsulate stem 
cells without relying on external stimuli (e.g. UV) that can be attenuated in large constructs 
or tissues. As expected, the cell carrier improved cell distribution in 3D printed polyHIPE 
scaffolds over standard suspension cell seeding. Finally, these polyHIPEs demonstrated 
strong potential as tissue engineered scaffolds by supporting long term viability and 
osteoblastic differentiation of carrier-delivered hMSCs. Overall, this approach has strong 
potential to improve bone regeneration with broader applications in stem cell delivery for 
regenerative medicine.  
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CHAPTER IV  
TUNABLE RELEASE OF BMP-2 FROM POROUS POLYHIPE MICROSPHERES 
 
4.1.  Introduction 
Limitations of current treatments for large bone defects and non unions has resulted in 
significant efforts to develop novel grafting materials with improved regenerative 
potential.230, 231 A promising approach has been the incorporation of bone morphogenetic 
proteins (BMPs) into biomaterial scaffolds. BMPs are a family of potent osteogenic 
factors active in bone tissue formation during embryonic development and skeletal 
repair.232, 233 Of the numerous members of the BMP family that have demonstrated 
efficacy in bone regeneration, BMP-2 has been the most extensively studied due to its 
putative role in osteoblastic differentiation, angiogenesis, chemoattraction, and cell 
signaling during fracture healing.101-104, 234, 235 As a result, numerous platforms have been 
investigated as carriers for this potent osteoinductive factor.1, 236-240  
Recently, delivery of recombinant expressed BMP-2 (rhBMP-2) in a collagen sponge 
was approved for commercial use by the FDA for treatment of specific spine, tibia, and 
craniofacial defects.107, 108 Since its release, this graft has demonstrated strong clinical 
efficacy and become a leader in the bone grafting market. Despite its regenerative 
potential, there were several safety concerns including inflammation, ectopic bone 
formation and neurological deficits.111 The bolus release of rhBMP-2 from the collagen 
sponge is rapidly cleared away from the injury and this necessitates the use of 
supraphysiological dosages to ensure therapeutic levels.241, 242 Although this bolus release 
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of growth factor has demonstrated improved bone formation, it also leads to undesirable 
off-target complications. 
The dynamic role that BMP-2 plays during various stages of the healing process 
suggests that a more local and sustained approach may be beneficial. It has been reported 
that there is an innate upregulation of ectopically osteoinductive BMP expression for 
several weeks following injury.11, 243 Sustained BMP levels over this period provides a 
robust osteogenic effect, allowing appropriate time for osteoprogenitor cell recruitment, 
retention, and differentiation.99, 103, 244 As such, numerous systems have been investigated 
to provide more physiologically relevant growth factor delivery profiles including 
hydrogels carriers, ceramic materials, and synthetic polymer scaffolds.245, 246 Although the 
mild processing conditions of hydrogels make them attractive carriers for growth factors, 
typical mesh sizes often result in burst release profiles with limited controls of kinetics 
without the addition of an affinity-based functionality (e.g. heparin).247-249 Surface-
modified ceramics that improve regeneration may experience reduced loading efficiencies 
during fabrication that raise scale-up concerns.1, 250, 251 As a result, encapsulation of BMPs 
into polymeric microspheres has emerged as one of the most promising methods to 
provide local and controlled delivery of these factors.  
The most widely studied of these systems is the fabrication of poly(lactic-co-glycolic 
acid) (PLGA) microspheres using emulsification-evaporation or porogen-leaching 
methods.239, 240, 252-256 257 These established techniques yield biodegradable particles with 
a range of porosities and sizes. Delivery of rhBMP-2 in these vehicles has been shown to 
significantly extend delivery profiles and improve bone regeneration in numerous in vivo 
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models. Kempen et al. reported a marked increase in ectopic and orthotopic bone 
formation with sustained rhBMP-2 release from a composite PLGA 
microsphere/poly(propylene fumarate) scaffold.258 Furthermore, Brown et al. 
demonstrated that microsphere mediated release could be used to enhance 
pharmacokinetic profiles in an injectable polyurethane scaffold and improve regeneration 
over current BMP-2 soaked scaffolds.259 Despite the strong potential of this traditional 
microsphere fabrication method, the requisite use of toxic solvents during fabrication 
poses significant challenges to bioactivity retention and commercialization. In addition to 
loss of therapeutic activity, protein denaturation resulting from unsatisfactory processing 
has been shown to introduce immunogenicity and toxicity concerns.260 Post fabrication 
loading of growth factors has been explored to minimize processing effects, but often 
results in reduced loading efficiency and elevated costs.246, 261 As a result, fabrication 
strategies that eliminate harsh processing conditions and allow for more efficient loading 
of costly therapeutics could offer several translational benefits for microsphere delivery 
of growth factors. 
We recently reported a method for solvent-free fabrication of porous microspheres 
using the principles of emulsion templating and fluid dynamics.262 This new methodology 
provides in-line loading of therapeutics and independent control over particle size and 
pore architecture, properties known to strongly influence release kinetics of encapsulated 
growth factors.117, 252, 263 Furthermore, the same macromer chemistry can be used for both 
the microsphere and the porous bone graft, which is expected to improve microsphere-
scaffold integration and mechanical integrity. Incorporation of microsphere delivery 
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systems with unmatched chemistries and porosities (e.g. hydrogel microspheres in PLGA 
graft) has been shown to significantly reduce mechanical properties.264, 265 As such, this 
novel fabrication technique provides significant advantages over traditional microsphere 
methods and has the potential to minimize commercialization and safety concerns.  
The focus of the current study was to establish fundamental relationships between 
microsphere properties and the resulting protein release kinetics. First, loading efficiencies 
and release kinetics were investigated as a function of microsphere diameter and pore 
architecture using a model protein. Bioactivity retention of encapsulated rhBMP-2 was 
then confirmed by monitoring luciferase activity in a BMP-responsive osteoblast reporter 
cell line. Next, the ability of rhBMP-2 loaded polyHIPEs to induce osteoblastic 
differentiation of human mesenchymal stem cells (hMSCs) was assessed using alkaline 
phosphatase (ALP) and mineralization assays. Finally, the effects of microsphere 
incorporation on composite scaffold architecture, compressive modulus, and yield 
strength were assessed to ensure no deleterious effects were observed. Collectively, this 
work aims to highlight the potential of polyHIPE microspheres to serve as a tunable, 
sustained release system and improve the regenerative capacity of polyHIPE bone grafts. 
4.2.  Materials and Methods 
4.2.1.  Materials 
Polyglycerol polyricinoleate (PGPR 4125) was donated by Paalsgard. All other 
chemicals were purchased and used as received from Sigma Aldrich unless otherwise 
noted. Ethylene glycol dimethacrylate (EGDMA) was filtered through an aluminum oxide 
column to remove the inhibitor monomethyl ether hydroquinone. 
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4.2.2.  Fabrication of BSA-FITC Loaded Microspheres 
Microspheres were fabricated via a fluidics double emulsion technique (w/o/w) 
adapted from Moglia et al., Figure 4.1.262 Briefly, primary high internal phase emulsions 
(HIPEs) were fabricated by combining the photocurable  macromer EGDMA with PGPR 
surfactant (10 or 30 wt%) and 2 wt% of the organically soluble photoinitiatior, 2,2-
Dimethoxy-2-phenylacetophenone (DMPA). Once mixed, an aqueous solution containing 
calcium chloride (1 wt%) and the model protein (200 ug/mL), bovine serum albumin – 
fluorescein isothiocyanate conjugate (BSA-FITC), was added to the organic phase (75% 
v) and emulsified using a FlackTek Speedmixer DAC 150 FVZ-K.  This primary HIPE 
was then injected dropwise (KD Scientific-100 Infusion Pump) into a continuously 
flowing external aqueous phase containing 3 wt% poly(vinyl alcohol) (PVA) aqueous 
solution and passed through UV excitation (UVP High Performance Transilluminator 365 
nm) to initiate radical crosslinking. Needle gauge, tubing diameter, aqueous flow rate, and 
surfactant concentration were varied to modulate particle and pore size using previously 
established relationships as outlined in Table 4.1. Collected microspheres were dried in 
vacuo for a minimum of 24 hours prior to characterization. Four model compositions were 
fabricated containing a particle diameter of ~900 or ~300 microns with a pore diameter of 
~45 or ~15 microns. 
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Figure 4.1. Schematic of microsphere fabrication. HIPE is injected through a needle 
parallel to the flow of 3 wt% PVA solution and polymerized via UV irradiation. 
Polymerized particles are collected and filtered prior to use. 
 
 
 
Table 4.1. Summary table of fabrication parameters including tubing diameter, needle 
size, flow rate, and surfactant compositions for model compositions. 
Composition 
Tubing 
ID Needle Size 
External 
Flow Rate 
HIPE 
Injection PGPR 
Part L-Pore S 1.6 mm 27 Ga 1.2 ml/min 0.2 ml/hr 30 wt% 
Part L-Pore L 1.6 mm 27 Ga 1.2 ml/min 0.2 ml/hr 10 wt% 
Part S-Pore S 0.8 mm 30 Ga 6.0 ml/min 1.0 ml/hr 30 wt% 
Part S-Pore L 0.8 mm 30 Ga 6.0 ml/min 1.0 ml/hr 10 wt% 
 
 
 
4.2.3.  SEM Analysis 
Average particle and pore diameter of varying compositions was determined using 
SEM (JOEL 6500) image analysis. A minimum of twenty-five particles, distributed over 
three fabrication batches, were coated with gold, imaged, and particle diameter measured. 
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Pore size measurements were completed on these particles using the first ten pores that 
crossed the median of each representative micrograph. Average particle (n = 25) and pore 
sizes (n = 100) for each polyHIPE microsphere composition are reported. 
4.2.4.  Loading Efficiency Model Protein 
Loading efficiency of each composition was determined using an accelerated release 
protocol. Prior to incubation, microspheres were crushed to increase surface area and 
minimize barriers to diffusion. Specimens were then placed in 2 mL centrifuge tubes and 
incubated in 1 ml DI water with agitation at 37C. After 24 hours, specimens were 
centrifuged to pellet the crushed particles and the aqueous phase removed. The pellet was 
then re-agitated with 1 ml DI water and incubated an additional 24 hours to remove 
residual protein. Protein concentration was determined using fluorescence spectroscopy 
(Tecan Infinite 200 Pro) by referencing a standard 10-point calibration curve prepared by 
measuring fluorescence of known concentrations of BSA-FITC. The concentration of 
BSA-FITC successfully encapsulated in the microsphere was then calculated and 
compared to the theoretical concentration loaded into the primary emulsion.  
4.2.5.  In Vitro Release Kinetics of Model Protein  
Microspheres containing BSA-FITC were placed in 2 mL centrifuge tubes and 
incubated in 1 mL DI water with agitation at 37C. At specified time points over 21 days, 
microsphere releasates were collected and replaced with 1 mL of fresh DI water. Daily 
protein release was determined using fluorescence spectroscopy (Tecan Infinite 200 Pro) 
by referencing a standard 10-point calibration curve prepared by measuring fluorescence 
of known concentrations of BSA-FITC. Cumulative release was determined by 
 100 
 
normalizing each cumulative time point to the total amount released over the experiment 
period.  
4.2.6.  Preparation of rhBMP-2 Loaded Microspheres 
Similar to BSA-FITC microsphere fabrication, an aqueous solution containing 
rhBMP-2 (E. coli expressed, R&D systems) was emulsified with EGDMA and surfactant 
to yield the primary HIPE. The rhBMP-2 HIPE was then polymerized and immersed in 
0.5 mL release medium (DMEM containing 0.1% FBS) and allowed to release for 4 days. 
Releasates were collected and diluted to a concentration of 100 ng/mL for testing of 
bioactivity.  
4.2.7.  Bioactivity Retention of Encapsulated rhBMP-2 with Reporter Cells 
A rapid assessment of bioactivity retention of rhBMP-2 loaded into polyHIPE 
scaffolds was performed by monitoring luciferase activity of a BMP responsive 
immortalized reporter (BRITER) cell line. Reporter cells were seeded at a density of 
100,000 cells/cm2 and cultured in growth media (DMEM + 10% FBS) containing 1 uM 4-
hydroxytamoxifen to minimize endogenous BMP expression. After 24 hours, culture 
media was removed and replaced with polyHIPE releasate (100 ng/mL rhBMP-2) or 
indicated concentration of stock rhBMP-2 solution (100, 60, 20, 0 ng/mL rhBMP-2). After 
3 hours, cells were lysed and luciferase activity measured using a Dual Luciferase 
Reporter Assay System (Promega). Relative luciferase activity was determined by 
normalizing BMP-2 dependent firefly luciferase activity to an internal cell density control 
via renilla luciferase activity.  
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4.2.8.  Osteogenic Differentiation of Human Mesenchymal Stem Cells 
Bone marrow-derived hMSCs were obtained as passage 1 from the Center for the 
Preparation and Distribution of Adult Stem Cells at Texas A&M Health Science Center 
College of Medicine, Institute for Regenerative Medicine at Scott & White through NIH 
Grant # P40RR017447. Cells were cultured to 80% confluency on tissue-culture 
polystyrene flasks in standard growth media containing Minimum Essential Media α 
(MEM α, Life Technologies) supplemented with 16.5% fetal bovine serum (FBS, Atlanta 
Biologicals) and 1% L-glutamine (Life Technologies) prior to passaging. All experiments 
were performed with cells at passage 3.  
Alkaline phosphatase activity of hMSCs cultured with polyHIPE releasate was 
determined by monitoring the conversion of p-nitrophenyl phosphate (PNPP, Thermo 
Scientific) to p-nitrophenol. hMSCs were seeded at a density of 15,000 cells/cm2  in 
standard growth media and allowed to adhere. After 24 hours, polyHIPE releasate or fresh 
rhBMP-2 as positive control (100 ng/mL) was added and changed every 3 days for 14 
days following measurement of ALP activity. Samples were lysed using thermal shock 
and incubated with PNPP Substrate for 30 min. ALP activity was determined as the rate 
of PNPP conversion to p-nitrophenyl by measuring the absorbance at 405 nm (Tecan 
Infinite M200Pro) and normalized to cell number obtained from dsDNA quantification 
(PicoGreen, Life Technologies). 
4.2.9.  Composite Scaffold Fabrication and Characterization 
Composite microsphere/polyHIPE scaffolds were fabricated by loading microspheres 
into redox initiated polyHIPEs prior to cure. Briefly, redox HIPEs were fabricated 
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according to established protocols with an organic phase comprised of 10 wt% PGPR and 
1 wt% benzoyl peroxide (BPO) initiator or trimethylaniline (TMA) as reducing agent.128 
Microspheres were added at 0, 5, 10, or 20 wt% (dried microsphere/ HIPE polymer phase) 
to both initiating and reducing emulsions and mixed to facilitate crosslinking. HIPEs were 
placed in a 37°C aluminum bead bath to facilitate crosslinking overnight. 
The effect of microsphere incorporation on polyHIPE compressive modulus and yield 
strength was investigated following ASTM D1621-04a. PolyHIPEs were sectioned into 
disks with a 3:1 diameter to height ratio (15 mm diameter, 5 mm thick) using an Isomet® 
saw. PolyHIPE specimens were compressed using an Instron 3300 at a strain rate of 50 
mm/s. The compressive modulus was calculated from the slope of the linear region and 
the compressive yield strength was identified, after correcting for zero strain, as the stress 
at the yield point or 10% strain. 
4.2.10. Statistical Analysis 
The data are displayed as mean ± standard deviation for each composition. An analysis 
of variance (ANOVA) comparison was used for multiple composition comparisons with 
a Tukey’s multiple comparison to analyze the significance of the data. A Student’s t-test 
was performed to determine any statistically significant differences if only two 
compositions were present. All tests were carried out at a 95% confidence interval 
(p<0.05). 
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4.3.  Results and Discussion 
4.3.1.  Fabrication and Characterization of PolyHIPE Microspheres 
To establish polyHIPE microspheres as a platform for sustained delivery of bioactive 
factors, the role of particle diameter and architecture on encapsulation efficiency and 
release kinetics of the model protein, BSA-FITC, was determined. We previously 
determined that a strict balance of fabrication parameters including external flow velocity 
and emulsion injection rates is necessary to ensure laminar flow and uniform particle 
generation.262 Prior to investigation of encapsulation efficiency and release kinetics, 
particle diameter and pore architecture was characterized to ensure there were no negative 
effects on emulsion stability after loading of the protein. A factorial design of two particle 
diameters and two pore sizes was utilized to fabricate four distinct compositions utilizing 
the parameters outlined in Table 4.1.  
First, control over external flow velocity was modulated to generate two distinct 
particle diameters. Tubing diameter of 1.6 mm was used with a flow rate of 1.2 ml/min to 
yield a flow velocity of 15 cm/min and large particles approximately 900 microns in size. 
An elevated flow velocity of 298 cm/min was achieved by decreasing tubing diameter to 
0.8 mm and increasing flow rate to 6.0 ml/min. As a result of the increased shear forces at 
the injection site, small diameter particles approximately 300 microns in diameter were 
formed. A significant advantage of polyHIPE microsphere fabrication is the facile 
modulation of particle size and architecture independent of each other. We have 
previously discussed the role of surfactant concentration on internal droplet size and 
resultant pore diameter in polyHIPE scaffolds. Using this knowledge, two particle 
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diameters ~45 microns to ~15 microns were fabricated by increasing surfactant 
concentrations from 10 wt% and 30 wt%. Representative micrographs particle diameter 
and pore size are provided in Figure 4.2 with quantification of particle and pore size 
provided in Table 4.2. 
 
 
 
 
Figure 4.2. Modulated particle diameter of model compositions with representative 
SEM micrographs (A-D). Modulated pore diameter of model compositions with 
representative SEM micrographs (E-H). From left to right: large particle-small pore, 
large particle-large pore, small particle-small pore, small particle-large pore. 
 
 
 
Table 4.2. Summary table of properties for model compositions including particle 
diameter (n=25), pore size (n=100), and loading efficiency (n=12). All data represents 
average ± standard deviation. 
 
Composition Particle Size (µm) Pore Size (µm) Loading Efficiency 
Part L-Pore S 908 ± 67 19 ± 5 92% ± 5% 
Part L-Pore L 933 ± 76 46 ± 11 85% ± 4% 
Part S-Pore S 282 ± 48 16 ± 5 83% ± 2% 
Part S-Pore L 333 ± 41 42 ± 12 71% ± 5% 
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4.3.2.  Improved Loading Efficiency with In-Line Encapsulation 
A significant drawback to growth factor incorporation is elevated production costs 
associated with inefficient loading of these therapeutics during the manufacturing process.  
Microsphere delivery systems fabricated using traditional emulsion-solvent evaporation 
methods often report encapsulation efficiencies below 70%.266, 267 Other systems, such as 
post-loaded scaffolds soaked in concentrated growth factor solutions, require elevated 
soak times and growth factor concentrations.113 Therefore, a fabrication method with the 
ability to efficiently load bioactive factor into delivery vehicles would overcome a 
significant barrier to clinical translation. A major advantage of combining emulsion 
templating with controlled fluidics is the ability to in-line load growth factor directly into 
the microsphere vehicle during fabrication. This is achieved through incorporation of a 
concentrated protein solution as the internal droplet phase during formation of the primary 
emulsion. After injection into the external phase, the continuous phase is then 
photopolymerized, trapping the protein within the porous structure of the microsphere. 
Encapsulation efficiency of the model protein, BSA-FITC, was determined in each 
composition by crushing and extracting the protein. Particles with large diameters had 
exceptionally high encapsulation efficiencies with 92% and 85% for small and large pore 
sizes, respectively (Table 4.2). The rapid polymerization of the prepolymer phase during 
fabrication trapped the in-line loaded protein, which combined with the lack of additional 
purification processes allowed for high encapsulation efficiency. Microspheres with small 
particle diameter experienced a minor decrease in encapsulation efficiency to 83% and 
71% for small and large pore sizes, respectively. It is hypothesized that the increased 
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surface area/volume ratio of small diameter particles allowed for more rapid diffusion of 
protein trapped in surface pores during fabrication. It is important to note that the 
fabrication setup was optimized over several iterations to achieve this high encapsulation 
efficiency. Specifically, microsphere collection was adjusted to minimize flow of the 
external aqueous phase over microspheres that had already exited the tubing, minimizing 
undesirable washout of protein after cure. Overall, the ability to achieve high 
encapsulation efficiency of a model protein within a multitude of particle and pore 
diameters demonstrates the versatility of the polyHIPE microsphere platform. 
4.3.3.  Effect of Microsphere Composition on Release Kinetics 
A primary aim of this work was to identify key relationships between microsphere 
property and release kinetics of a model protein. Achieving physiologically relevant 
delivery profiles of osteogenic factors is a critical design criterion that has yet to be 
sufficiently addressed in clinically available systems. Although some level of burst 
release, or rapid diffusion of factor out of the vehicle immediately following implantation, 
can be desirable and initiate fracture healing, it has been demonstrated that sustained 
delivery of osteogenic factor is also needed to allow appropriate time for osteoprogenitor 
cell recruitment and differentiation.243 To this end, delivery profiles of polyHIPE 
microspheres were monitored over 21 days to assess levels of burst and sustained release, 
Figure 4.3. Unlike traditional delivery of small, hydrophobic compounds, release of 
growth factors from polymeric systems most often proceeds through diffusion of the 
protein through water filled pores.268 Due to high molecular weight, growth factor release 
is not achieved by diffusion through the hydrophobic polymer phase. Passive diffusion of 
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protein out of water filled pores is referred to as the ‘intrinsic’ or ‘true-release’ mechanism 
of porous polymeric systems.268 To further understand release kinetics, extensive study 
has been performed to identify rate-controlling mechanisms in these systems.268 In this 
study we investigate the role of several rate-controlling mechanisms on model protein 
release including surface area-to-volume ratio, path length/tortuosity, and protein 
adsorption. The use of a double emulsion, controlled fluids fabrication system, allows for 
independent modulation of microsphere property and more systematic study of these 
mechanisms. The effect of surface area-to-volume ratio on release kinetics was first 
assessed by fabricating two distinct sets of microspheres, each set containing a large and 
small diameter particle of similar pore size. As expected small microspheres had a higher 
level of burst release after 24 hours, ranging from ~65% to ~78%, Figure 4.3B.  
Microspheres with a reduced surface area-to-volume ratio (large diameter) experienced a 
decreased 24 hour burst ranging from ~25% to ~47%. We attribute this difference in burst 
profile to the 3-fold increase in relative surface area for smaller particles, allowing for 
more rapid diffusion of protein away from the particle surface. Furthermore, the increased 
path length of large diameter particles resulted in ~80% of protein released after 7 days as 
opposed to ~95% protein release for small diameter particles. 
In addition to characterizing the effect of particle diameter on release kinetics, the 
effect of pore architecture and tortuosity was assessed, Figure 4.3C. Tortuosity, a unit-
less measure of path length through a porous medium relative to the end-to-end path 
length, is hypothesized to act as a primary tool in modulating release kinetics. Specifically, 
as pore size decreases, the subsequent increase in tortuosity is predicted to reduce protein 
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diffusion out of the microsphere. To investigate this mechanism, two distinct sets of 
microspheres were fabricated, each set containing two unique pore sizes for particles of 
similar diameter. For both particle diameters, a decrease in pore size resulted in more 
sustained release. Release after 72 hours decreased from ~80% to ~60% for large particles. 
A smaller change in protein release was observed after 72 hours for small particles with 
varied pore size. This was attributed to the high level of burst release discussed previously. 
However, increased tortuosity delayed 95% release of the protein from day 5 to day 9 for 
small diameter particles. In addition to increased tortuosity, it was hypothesized that a 
decreased pore size resulted in increased protein adsorption as a result of larger surface 
area present in the particle. Although protein adsorption may lead to incomplete release, 
protein-material interactions have been demonstrated as a potent rate-controlling 
mechanism in polymeric delivery systems.269 
These studies were designed to provide introductory investigation into the potential of 
polyHIPE microspheres as controlled delivery vehicles. Additional methods can be 
explored to further modulate release kinetics. Given the slow degradation rates of 
EGDMA scaffolds, degradation-based release was not hypothesized to play significant 
role in these studies. However, selection of alternative biodegradable prepolymers 
fabricated with a closed-pore architecture would allow for introduction of yet another rate-
controlling mechanism, further enhancing the tunability of this system. We have 
previously demonstrated that closed pore morphologies can be achieved with this system 
by changing to an aqueous initiator.130 
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Figure 4.3. Tuning release profiles of BSA-FITC from polyHIPE microspheres. Daily 
and cumulative release profiles for all model compositions (A). Effect of particle size on 
release kinetics for large (45um) and small (15um) pore size (B). Effect of pore diameter 
on release kinetics for large (900um) and small (300um) particle size (C). All data 
represents average ± standard deviation for n = 3. 
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4.3.4.  Bioactivity Retention of Encapsulated rhBMP-2  
A significant hurdle to translation of BMP-2 loaded scaffolds is developing a 
fabrication method that retains therapeutic activity of encapsulated factors. Processes that 
require extensive purification, exposure to heat, or interaction with toxic solvents are 
prone to reduced bioactivity retention.270 The photopolymerization method utilized here 
crosslinks the continuous phase of the primary emulsion within minutes at room 
temperature and eliminates the need for additional purification. The lack of organic 
solvents in this process provides the advantage of eliminating toxic leachables that may 
denature rhBMP-2 and raise concerns over biocompatibility. A significant step in the 
investigation of polyHIPE microspheres as a viable growth factor delivery system is to 
confirm growth factor loaded into the primary emulsion retains therapeutic activity after 
fabrication. To this end, a BMP responsive reporter cell was utilized as an initial test of 
bioactivity, Figure 4.4. Abbreviated BRITER, these immortalized calvarial osteoblasts 
are modified with a BMP responsive dual luciferase reporter construct.271 Upon exposure 
to exogenous BMP-2, these cell exhibit a prompt and robust response, allowing for rapid 
detection of BMP activity. Luciferase activity was first determined in response to selected 
concentrations of non-encapsulated rhBMP-2 and utilized to determine a reference activity 
profile. rhBMP-2 was then encapsulated in high internal phase emulsion and 
photopolymerized.  Encapsulated factor was extracted from the scaffold over 4 days and 
exposed to reporter cells for 3h followed my measurement of luciferase activity. Protein 
concentration extracted from primary emulsions was determined using established 
CBQCA quantification assays and normalized to a concentration of 100 ng/mL (data not 
 111 
 
shown). As shown in Figure 4.4, encapsulated rhBMP-2 retained ~60% activity compared 
to non-encapsulated BMP-2 of equal concentration. BRITER cells with no exogenous 
BMP-2 exposure were used as negative control and demonstrated negligible activity. 
 
 
 
 
Figure 4.4. Normalized FFLuc activity of BRITER cell line treated with releasates taken 
from rhBMP-2 loaded microspheres. Percent bioactivity retention determined by 
comparison to FFLuc of known rhBMP-2 stocks. 
 
 
 
 
4.3.5.  Osteoblastic Differentiation of hMSCs Induced by rhBMP-2 Release  
Next, an additional measure of bioactivity was performed to investigate if extracted 
rhBMP-2 could elicit osteoblastic differentiation of human mesenchymal stem cells. In 
this study, alkaline phosphatase activity was characterized as an early marker of 
osteoblastic differentiation, Figure 4.5. The upregulation of ALP, an enzyme active in 
mineral formation and dephosphorylation processes of osteoblasts, is a well-established 
response to exposure of exogenous BMPs.235 hMSCs were cultured with rhBMP-2 
encapsulated and released form polyHIPE scaffolds, with non-encapsulated rhBMP-2 or 
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osteogenic media used as positive controls. Additionally, cells cultured in standard growth 
media without an osteoinductive agent were used as a negative control. After 2-week 
exposure, encapsulated rhBMP-2 promoted a similar osteoblastic response as hMSCs 
cultured in osteogenic (dexamethasone supplemented) conditions. Non-encapsulated 
rhBMP-2 had the highest activity with a ~4 fold increase over standard growth conditions. 
There are several mechanisms that may explain the observed difference in bioactivity for 
factor released from polyHIPEs compared to stock rhBMP-2. Most likely, early 
degradation of the factor occurred during the incubation period utilized for protein 
extraction. Bone morphogenetic proteins have been shown to possess low stability with 
therapeutic half-life being a function of incubation conditions such as solvent, 
temperature, and time in solution.272-274 Stabilizing saccharides such as trehalose and 
heparin are often utilized to improve bioactivity retention in microsphere delivery systems 
studied for bone tissue engineering. Trehalose, a non-reducing disaccharide, serves as 
thermal protectant and improves stability under lyophilization and storage conditions.275 
Furthermore, Zhao et al. and Bramono et al. demonstrated heparin, a sulfated 
polysaccharide, could be used to limit degradation and prolong half-life of BMP-2 in 
media, up to 20-fold in cases.276, 277  Although this study suggests that there is some 
reduction in bioactivity, the ability of encapsulated factor to promote measurable 
osteoblastic differentiation after release from polyHIPE scaffolds in the absence of 
additional stabilization demonstrates the utility of the polyHIPE microspheres. In addition, 
exposure of polyHIPE releaseate had no deleterious effects on cell density during the 
culture period, confirming no toxic leachable are present after microsphere fabrication. As 
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these preliminary studies indicate the ability to retain bioactivity of encapsulated factor 
after HIPE fabrication, current focus will be placed on extending therapeutic activity 
during duration of the targeted release profiles through investigation of stabilizing 
molecules.  
 
 
 
 
Figure 4.5. Effect of rhBMP-2 loaded polyHIPE releasate on cell density (A) and 
alkaline phosphatase activity (B) of hMSCs cultured with releasate for 14 days. Cells 
were cultured in fresh solution of stock rhBMP-2 (BMP-2) and osteogenic media (OM) 
as positive control, and growth media (GM) as negative control. All data represents 
average ± standard deviation for n = 4. The * and ° represent significant difference 
(p<0.05) between BMP-2 or GM and indicated compositions for density or ALP activity. 
 
 
 
4.3.6.  Effect of Microsphere Incorporation on Composite PolyHIPE Properties 
Ideally, an injectable bone graft contains a porous architecture to facilitate cellular 
infiltration, and compressive properties sufficient to stabilize the injury and provide 
mechanical stimuli to encourage regeneration.20, 27 PolyHIPE scaffolds are unique in their 
ability to combine high porosities with uniform pore structures with mechanical properties 
that approach those of cancellous bone. Therefore, it is critical that any platform utilized 
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to provide targeted bioactivity not compromise load bearing potential of the graft. To this 
end, the effect of microsphere incorporation on compressive modulus and strength of 
injectable scaffold was characterized as a function of microsphere structure and percent 
incorporation. It was hypothesized that providing similar chemistry and pore architecture 
to that of the polyHIPE monoliths would limit effects on mechanical properties. An initial 
study of polyHIPE compressive modulus and strength was performed after adding 5 wt% 
of each of the four model compositions to assess potential effects of particle and pore size. 
At this level of incorporation, no statistical were differences observed between the blank 
polyHPE and any microsphere loaded composition, Figure 4.6A. This is promising as it 
demonstrates the ability to tune release profiles without impacting scaffold mechanical 
properties. To further highlight the range of this system, additional studies were performed 
to identify the compressive modulus and strength for increasing amounts of particle 
incorporation.  Microspheres with surfactant concentration matched to that of the neat 
polyHIPE scaffold were added at increased amounts of 10 and 20 wt%, Figure 4.6B. A 
non-significant decrease in compressive properties was observed for 10 wt%, with ~50% 
reduction in compressive properties observed at 20 wt% incorporation. It is hypothesized 
that as the number of particles increased, non-uniform dispersion within the emulsion 
resulted in the formation of aggregates and limited proper integration with the 
surrounding, curing HIPE. Uniform dispersion within the scaffold is critical as it has been 
observed that a lack of interfacial interactions between scaffold and microsphere can result 
in a decrease of composite mechanical properties.258 Kempen et al. demonstrated that 
increasing amounts of both PLGA and PPF microspheres added into a porous PPF scaffold 
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resulted in a significant decrease in compressive properties. Although a decrease was 
observed with increasing incorporation of PPF microspheres, the availability of covalent, 
interfacial interactions between scaffold and microsphere of matching chemistry resulted 
in increased compressive properties over PLGA microspheres. From this, it is anticipated 
that if uniform dispersion within our scaffold is maintained, allowing for appropriate 
interfacial bonding between methacrylate functional groups of sphere and emulsion, 
mechanical effects will be reduced. Current studies are exploring modified double barrel 
syringes that allow for more homogenous mixing and distribution of microspheres in the 
injectable HIPE. Furthermore, it is not anticipated that 20 wt% microsphere incorporation 
will be needed to promote an osteogenic response. Microsphere incorporation ranging 1-
10 wt% has been demonstrated suitable to promote new bone formation utilizing loaded 
protein concentrations similar to those presented here.118, 119, 259, 278 If a more robust 
response is desired, BMP-2 concentration loaded into the primary emulsion can be easily 
modulated to improve activity as has been observed in similar microsphere delivery 
systems.278 
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Figure 4.6. Effect of microsphere particle size and pore size on composite scaffold 
compressive modulus and strength for 5 wt% incorporation using four model 
compositions (A). Effect of increasing microsphere incorporation (5, 10 and 20 wt%) on 
composite scaffold compressive modulus and strength (B). All data represents average ± 
standard deviation for n = 3. The * and ° represent significant difference (p<0.05) for 20 
wt% compressive modulus or strength and other indicated compositions. 
 
 
 
In addition, incorporation of microspheres into the polyHIPE scaffold will provide an 
additional variable to tune release of osteoinductive factors in our system. Multiple studies 
have reported on the ability to improve sustained release profiles of growth factor 
delivered from microsphere vehicles by imbedding into secondary scaffolds.119, 239 These 
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studies have reported success in promoting osteogenic activity in vitro and in vivo. 
Subsequent studies will assess the ability of polyHIPE scaffolds embedded with rhBMP-
2 loaded microspheres to promote osteoblastic differentatin of mesenchymal stem cells 
cultured on the scaffold surface. 
4.4.  Conclusions 
The aim of this study was to improve the osteoinductive potential of polyHIPE grafts 
by utilizing a new polyHIPE microsphere-based growth factor delivery system and 
establish the key relationships between microsphere properties and resultant protein 
release kinetics. The independent and combined effects of particle and pore size on burst 
and sustained release of proteins was determined. Bioactivity retention of the encapsulated 
BMP-2 growth after emulsion fabrication and photopolymerization processes was 
confirmed with demonstrated ability of the released BMP-2 to induce osteogenic 
differentiation of hMSCs. Finally, microsphere loaded composites were characterized to 
demonstrate that microsphere incorporation did not have deleterious effects on 
compressive properties. Overall, this investigation provides key insights critical to the 
design of an osteoinductive polyHIPE system capable of providing physiologically 
relevant delivery profiles. 
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CHAPTER V  
CONCLUSIONS 
 
5.1.  Summary  
The work presented here aims to develop an improved bone replacement based on the 
emulsion templating platform. These studies detail methods of fabricating injectable and 
porous grafts with improved function in clinically relevant environments, cell delivery 
platforms for improved loading of polyHIPE scaffolds, and porous microspheres for 
targeted growth factor delivery. Together, these advancements address limitations of 
current standards of care, including autologous and allogenic grafts, by providing a readily 
available bone replacement that has been optimized to actively guide bone regeneration. 
Injectable polyHIPEs with improved resistance to oxygen inhibition were fabricated 
utilizing the thiol monomer pentaerythritol tetrakis(3-mercaptoproprionate), and the 
biodegradable macomer, propylene fumarate dimethacrylate. Thiol-methacrylate 
polyHIPEs exhibited rapid cure and improved network formation under oxygen rich 
conditions and retained the ability to modulate key properties including porosity, 
architecture, and compressive properties. Furthermore, thiol-methacrylate polymerization 
introduced a potent tool to tune the hydrolytic degradation rates of these injectable 
scaffolds. Matching the degradation profile of a tissue engineered scaffold with the healing 
rate of the native tissue is critical component of improving defect regeneration.  
To improve the regenerative capacity of polyHIPE grafts, poly(ethylene glycol)-
dithiothreitol hydrogels were utilized to improve seeding and distribution of human 
 119 
 
mesenchymal stem cells (hMSCs) within 3D printed polyHIPEs. These in situ cell carriers, 
fabricated from biodegradable, redox initiated hydrogels, exhibited tunable 
polymerization rates, uniform cell distribution, and viable release of encapsulated stem 
cells. Regenerative potential of these composite, cell-laden polyHIPEs was demonstrated 
by characterizing osteoblastic differentiation of hMSCs released onto 3D printed 
polyHIPEs. This in situ approach to cell seeding permits facile use of patient specific cells 
that can be incorporated in tissue engineered scaffolds with minimal processing in the 
surgical suite.  
Finally, additional osteoinductive character was added to the graft through the solvent-
free fabrication of porous, in-line loaded microspheres capable of efficiently delivering 
osteoinductive factors. Modulation of polyHIPE microsphere property provided tools for 
tuning release kinetics without compromising compressive properties. Methods were 
developed to characterize bioactivity retention of encapsulated BMP-2 factor using a 
luminescence based reporter cell line and functional MSC differentiation assays. These 
studies demonstrate the strong potential of polyHIPE microspheres to improve bone 
regeneration through growth factor delivery and decrease manufacturing costs through 
utilization of more efficient fabrication and loading techniques.  
Collectively, these studies highlight the strong potential of polyHIPE scaffolds to serve 
as an improved bone replacement with the ability to actively guide bone regeneration. 
Although the technologies developed in this work hold advantages in bone tissue 
engineering, the platforms utilized here are tunable in nature and be easily applied to the 
engineering of other target tissues.  
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5.2.  Significance of Work 
To date, no system has been able to fully match the healing potential that autologous 
tissue possesses due to its unique combination of osteoconductive (collagen-based ECM), 
osteoinductive (growth factors and cytokines), and osteogenic (stem and osteoprogenitor 
cells) properties. This work aimed to develop a polyHIPE graft that was capable of actively 
guiding bone regeneration by modeling these natural processes that make autologous 
grafting the current standard of care. Specifically, this work investigated PFDMA 
polyHIPE scaffolds as a porous and osteoconductive substrate to support bone repair. 
Furthermore, platforms to induce osteoinductive and osteogenic activity were investigated 
through development of polymeric delivery vehicles that allow for incorporation of bone 
morphogenetic proteins and mesenchymal stem cells. Combined, these technologies 
provide the foundation for developing novel, patient specific polyHIPE bone replacements 
with improved healing potential. 
In Chapter 2, an alternative polymerization mechanism was explored to improve 
polymerization times and network formation in clinically relevant, oxygen rich 
enviornments. Redox initiated polyHIPEs have demonstrated a host of properties that are 
advantageous for bone repair. However, these studies were performed in a controlled 
environment that does not adequately represent all the challenges that are present in vivo. 
Retaining established properties, including rapid cure, uniform pore architecture, and load 
bearing potential, is dependent on the ability to obtain uniform high network formation in 
oxygen rich environments. Addressing the problem of oxygen inhibition has been 
discussed extensively in photopolymerized systems, however it has not been addressed 
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sufficiently in injectable systems.155 Development of an injectable, highly porous graft 
that undergoes rapid polymerization in vivo is a major challenge in bone tissue 
engineering. This work demonstrated a thiol-methacrylate polymerization route that 
would be better immune to oxygen inhibition and provide an additional tool for 
modulating scaffold degradation rate. Differences in patient demographics, including age, 
health, and severity of injury, make developing a single graft capable of matching healing 
rate extremely difficult. As a result, modulating thiol concentration is a critical tool as it 
allows for rapid tuning of ester-based hydrolysis of the polyHIPE scaffold. 
In Chapter 3, a platform for improved seeding of stem cells in tissue engineered grafts 
was developed. Mesenchymal stem cells play a significant role in regeneration of 
musculoskeletal tissues through recruitment and direction of progenitor cells, promotion 
of angiogenesis, and modulation of immune response.192 Designing a biomaterial carrier 
that improves placement, retention, and survival of transplanted stem cells is currently a 
major focus in regenerative medicine as the hostile environment of injured tissue often 
yields the direct injection of stem cells into the defect site ineffective.81 This work 
provided a method of encapsulating stem cells in biodegradable hydrogel, protecting them 
from early removal and subsequently improving the number and placement of stem cells 
seeded in a 3D printed polyHIPE graft. Development of a composite polyHIPE-hydrogel 
graft has the additional advantage of retaining requisite mechanical properties that are 
often lacking in hydrogel carriers alone. In addition to the direct effect this platform could 
have on improving regeneration, methods were developed to better characterize 
osteogenic activity on polyHIPE grafts through characterization of ALP and 
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mineralization markers. These methods can be used and further adapted to investigate 
osteogenic potential as additional technologies are introduced into polyHIPE grafts. 
Furthermore, this work provides a platform that can be further adapted (e.g. bioactivity, 
degradation profiles, and cell type) for incorporation of stem cells therapies into 
engineering strategies for other target tissues, including cardiac and nerve applications. 
In Chapter 4, growth factor delivery was explored as a means to improve the 
osteoinductive character of our grafts. Through this work, a solvent-free method for 
generating porous, growth factor loaded microspheres was established via combination of 
emulsion templating and controlled fluidics fabrication techniques. Development of a 
cost-efficient growth factor delivery system that has high loading efficiency and tunable 
release kinetics is a significant challenge in tissue engineering. The improvements this 
system presents in processing and purification offer the potential to maximize loading 
efficiency while simultaneously minimizing scale up concerns. These studies produced 
methods to characterize and modulate protein release, as well as assess bioactivity 
retention of encapsulated factor, all protocols that can be easily adapted to a wide range 
of bioactive factors. Furthermore, this system provides a baseline fabrication method that 
can be further modified to deliver multiple growth factors simultaneously. Numerous 
studies have probed the benefits of multiple factor delivery and worked to design systems 
that better mimic the complex chemical environment of native tissue.253  
Overall, this work demonstrates the ability to tune polyHIPE grafts to achieve desired 
physical and mechanical properties in clinically relevant settings. Furthermore, the tunable 
nature of the emulsion templating platform allows it to be easily tuned for the 
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incorporation of stem cells and bioactive factors. Although each component of this work 
aimed to provide a specific advantage to our polyHIPE bone graft, the broader impact of 
this work lies in the development of platforms and methods that can be easily modified to 
achieve regeneration in any target tissue.  
5.3.  Challenges and Future Directions 
This work details the development of tunable polyHIPE scaffolds with improved 
healing potential through incorporation of stem cells and osteoinductive factors. Despite 
the demonstrated improvements in scaffold function and osteogenic potential in vitro, 
additional studies are needed to further optimize scaffold composition and assess bone 
formation in vivo. 
A primary focus of this work was the modification of polyHIPE scaffolds, and 
development of assaying techniques, to better probe hMSC-polyHIPE interactions.  It was 
demonstrated that polyHIPE scaffolds support desired markers of stem cell attachment, 
viability, and osteoblastic differentiation. However, these studies were performed in a 
highly controlled in vitro setting that relied on the adsorption of serum proteins to facilitate 
cell attachment. It is probable that cellular infiltration and migration would be reduced in 
vivo due to a lack of native binding sites for host cells, a phenomenon observed in other 
synthetic polymer systems.94 Developing a hybrid polyHIPE scaffold with ECM-like 
surface modifiers would present an intriguing approach to encouraging native cell 
infiltration, as well as a potent tool to controlling cell fate. Integrin-mediated control of 
osteoblastic differentiation has been explored previously as a means of improving bone 
regeneration.185 The work presented here demonstrated proof of principle protocols that 
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allow for facile incorporation of functionalized protein into polyHIPE scaffolds. Pore 
surfaces of modified scaffolds stained positive for gelatin incorporation and promoted cell 
attachment in serum free culture. This same approach could be utilized to crosslink a 
multitude of ECM-like proteins to the pore surface. Streptococcal collagen-like proteins 
are engineered proteins that form a triple helix similar to mammalian collagen, but with 
the added advantage of being able to provide precise control over presented integrin 
binding domains. Systematic investigation must first be completed to identify integrin-
mediated signaling pathways most active in osteoblastic differentiation, followed by 
synthesis of the corresponding designer protein. Common methods for identification 
include antibody blocking targeted integrin receptors and monitoring the effect on gene 
expression using the osteoblastic markers, alkaline phosphatase, RUNX2, osteopontin, 
osteocalcin, and collagen I. Next, attachment, viability, and differentiation protocols 
discussed in this work could be implemented to ensure improvements in desired cell 
markers over a two week culture period. 
The ability to delivery cells within a polyHIPE scaffold was a key advancement 
presented in this work. In vitro studies demonstrated significant improvement in cell 
distribution and retention over standard suspension seeding methods. Despite these 
improvements, it is critical that in vivo improvements be investigated as implantation into 
diseased or injured tissue is known to pose significant challenges to cell retention.82 A 
proof of principle study investigating cell retention could be performed utilizing a 
subcutaneous model in Sprague-Dawley rats. A primary advantage of the in situ cell 
carrier developed here is that it allows for facile incorporation of host specific cells in the 
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surgical setting. As such, bone marrow derived stromal cells can be isolated from femoral 
limbs, expanded in vitro, and injected into a 3D printed polyHIPE. Monitoring retention 
and migration of transplanted cells can be performed through RT-PCR analysis of gender 
specific genes, fluorescent tagging using standard immunostaining protocols, or magnetic 
resonance imaging of magnetically labelled cells. It is probable that in vivo application 
may alter degradation profiles over those observed in vitro. If accelerated degradation 
were to occur, it is possible that transplanted cells may be removed before they have 
substantial time to adjust the regenerative microenvironment of damaged tissue. If 
necessary, degradation rate can be adjusted by modulating the number of DTT linkages 
present in the macromer backbone. This would allow for retention of established hydrogel 
properties while ensuring cells remained protected and present long enough to produce a 
robust trophic effect. 
Treatment of musculoskeletal defects is a unique challenge in tissue engineering as 
these injuries are often accompanied by large volumetric tissue loss, compromising native 
vasculature and nutrient transport systems. As a result, it is necessary to engineer systems 
that promote both osteo-and angiogenesis. BMP-2 delivery is a potent method for 
improving osteogenic activity and has been shown to upregulate production of angiogenic 
factors in osteoblasts, however direct delivery of angiogenic factors, such as vascular 
endothelial growth factor, has been shown to provide synergistic improvements in bone 
healing.253 Controlled co-delivery of these factors would provide a platform that could 
better explore the complex feedback loops present in bone healing and vascularization 
signaling pathways. The emulsion templating based-controlled fluidics fabrication method 
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would allow for development of microsphere delivery systems capable of co-delivery of 
these factors. Core-shell systems allow for controlled, sequential delivery of multiple 
therapeutic agents by encapsulating them in distinct spatial locations of the delivery 
system and providing unique temporal release profiles.279 The present fluidics system 
would be modified with a coaxial needle to allow dual injection of two primary emulsions, 
each containing a distinct bioactive factor. These emulsions could be fabricated with 
unique pore architectures to allow for independent control over release kinetics. Although 
modulation of particle and pore size provides independent tools to control protein release 
kinetics, it is probable that a more sustained release profiles will be desired. To extend 
release, closed pore microspheres could be investigated to change the release mechanism 
from solely passive diffusion, to degradation mediated release. Upon degradation of the 
pore walls, encapsulated protein would be allowed to diffuse out into the surrounding 
scaffold. Modulation of internal phase volume fraction, or use of a water soluble initiator 
could facilitate formation of closed pore polyHIPEs. Although the methacrylated 
macromer utilized for microsphere fabrication here does not degrade in a suitable time 
frame, other systems explored here, such as thiol-methacrylate systems, could provide 
more rapid and controlled degradation rates. 
Finally, to fully assess the clinical potential of the polyHIPE system developed in this 
work, in vivo osteogenesis must be monitored. The rabbit femoral condyle plug model 
provides a rapid, high throughput method for investigation of biocompatibility, host 
response and osteogenesis.280 It is hypothesized that the platforms developed in this work 
would provide synergistic improvements in bone regeneration. To confirm this 
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hypothesis, a factorial study design must be implemented to investigate the individual and 
synergistic effects of scaffold surface modification, stem cell delivery, and growth factor 
delivery. MicroCT radiographic analysis would be used to monitor temporal changes in 
mineralized tissue formation over 8 and 16 weeks. Next, histological analysis using H&E 
and trichrome stains would be used to evaluate inflammation, vascularization, and bone 
formation across various regions of each defect. Sections would be subjectively scored, 
evaluated, and compared to blank defect controls and clinical calcium phosphate controls. 
Finally, microscale integration of the scaffold with the host tissue will be assessed by 
measuring peak loads of mechanical push out testing. Completion of this study would be 
invaluable in the development of selection criteria needed to balance improvements in 
healing with potential scale up and manufacturing costs. 
Although additional investigation is required to confirm polyHIPE grafts are a viable 
bone grafting option, the technologies detailed in this work provide a promising platform 
that can be built upon to ensure all necessary criteria are met to support in vivo 
regeneration. The methods established here allow for characterization of all major tenets 
the tissue engineering paradigm, including scaffold properties, cell-material interactions, 
and bioactive factor delivery. In summary, the presented work, combined with these 
proposed studies, will provide knowledge critical to the development of a polyHIPE graft 
capable of actively guiding bone regeneration. 
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